Chimeric antigen receptors specific for MAGE-A4 and uses thereof
By designing a chimeric antigen receptor (CAR) that specifically binds to the MAGE-A4 peptide antigen in the HLA-A2 background, the problem of the lack of MAGE-A4-specific CARs in existing technologies has been solved, enabling effective treatment and immune response for MAGE-A4-expressing cancers.
Patent Information
- Application Number
- CN202080052900.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-07
- Filing Date
- 2020-07-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-07-24
AI Technical Summary
There is a lack of chimeric antigen receptors (CARs) that specifically bind to the MAGE-A4 antigen in the current technology, and there are no effective methods for producing and using such agents for treatment and diagnosis.
A chimeric antigen receptor (CAR) that specifically binds to the MAGE-A4 peptide antigen in the MHC (HLA-A2) background was designed and developed. It contains an anti-MAGE-A4 single-chain variable fragment (scFv) domain, a hinge, a transmembrane domain, and a signal transduction domain for engineering T cells to target MAGE-A4-expressing cancers.
It enhanced the cytotoxicity of T cells against MAGE-A4-expressing cancers such as melanoma and multiple myeloma, achieving effective anti-tumor activity and immune response.
Smart Images

Figure BDA0003482079210000421 
Figure BDA0003482079210000422 
Figure BDA0003482079210000441
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 878,125, filed on July 24, 2019; U.S. Provisional Patent Application No. 63 / 020,177, filed on May 5, 2020; and U.S. Provisional Patent Application No. 63 / 021,407, filed on May 7, 2020, each of which is incorporated herein by reference in its entirety for all purposes.
[0003] Reference to a sequence listing
[0004] This application incorporates by reference file 10600WO01-Sequence.txt, created on July 24, 2020 and filed in a computer-readable form listing containing a 123,650 byte sequence. Technical Field
[0005] The present disclosure provides chimeric antigen receptors (CARs) and engineered cells comprising such CARs, which are specific for melanoma associated antigen A4 (MAGE-A4), and methods of use thereof. Background Art
[0006] MAGE-A4 or melanoma associated antigen A4 is a cancer testis antigen (CTA) on chromosome X. The function of MAGE-A4 is unknown, but it may be involved in cell cycle progression / regulation, transcriptional control, cell survival and / or apoptosis. For example, overexpression of MAGE-A4 has been shown to promote the growth of spontaneously transformed oral mucosal cells and inhibit the growth arrest of cells in G1.
[0007] MAGE-A4 is abundantly expressed by many different histological types of tumors, such as head and neck squamous cell carcinoma, lung cancers such as non-small cell lung cancer, esophageal squamous cell carcinoma, colon cancer, bladder cancer, mucosal and cutaneous melanomas, ovarian cancers such as serous carcinomas, and uterine cancer, but in normal healthy adult tissues, MAGE-A4 expression is restricted to the testis.
[0008] The ability of the MAGE-A4 antigen to elicit an immune response as well as its restricted expression pattern make MAGE-A4 a good candidate for cancer immunotherapy.
[0009] Adoptive immunotherapy, which involves the transfer of autologous antigen-specific T cells generated in vitro, is a promising strategy for the treatment of viral infections and cancer. T cells for adoptive immunotherapy can be generated by expansion of antigen-specific T cells or by redirecting T cells through genetic engineering.
[0010] New specificities of T cells have been successfully generated by genetic transfer of transgenic T cell receptors or chimeric antigen receptors (CARs) (Jena, Dotti et al. 2010). CARs are synthetic receptors consisting of targeting moieties associated with one or more signaling domains in a single fusion molecule. Typically, the binding portion of a CAR consists of an antigen binding domain of a single-chain antibody (scFv), including light and heavy chain variable fragments of a monoclonal antibody connected by a flexible linker. The signaling domain of the first generation of CARs is from the cytoplasmic region of CD3ζ or the Fc receptor γ chain. The first generation of CARs has been shown to successfully redirect the cytotoxicity of T cells. However, CARs have failed to provide prolonged amplification and anti-tumor activity in vivo. Signaling domains from co-stimulatory molecules as well as transmembrane domains and hinge domains have been added to form second and third generation CARs, leading to some successful human therapeutic trials. For example, CAR redirection of T cells specific to the B cell differentiation antigen CD19 has shown significant efficacy in the treatment of B cell malignancies, while TCR redirection of T cells has shown benefits in patients with solid cancers. Stauss et al. describe strategies to modify therapeutic CARs and TCRs for the treatment of cancer, for example, to enhance antigen-specific effector function and limit the toxicity of engineered T cells (Current Opinion in Pharmacology 2015, 24:113-118).
[0011] There is an unmet need for new targeting agents based on CARs that specifically bind to the MAGE-A4 antigen and methods for producing and using such agents in therapeutic and diagnostic settings. Summary of the invention
[0012] The present disclosure provides a chimeric antigen receptor (CAR) generated against a MAGE-A4 peptide antigen in the context of MHC (HLA-A2). In some embodiments, the CAR sequence has specific binding to a small peptide MAGE-A4 286-294 or MAGE-A4 230-239 presented by HLA-A2.
[0013] On the one hand, the present disclosure provides a melanoma-associated antigen A4 (MAGE-A4)-specific chimeric antigen receptor (CAR), wherein the MAGE-A4-specific chimeric antigen receptor interacts with amino acids 286-294 or 230-239 of SEQ ID NO: 32 or a portion thereof, and wherein the MAGE-A4-specific CAR specifically binds to an HLA-binding MAGE-A4 polypeptide. In some embodiments, the MAGE-A4-specific CAR includes from N-terminus to C-terminus: (a) an extracellular ligand binding domain including an anti-MAGE-A4 antigen binding domain; (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain including a co-stimulatory domain and a signaling domain. In some embodiments, the extracellular ligand binding domain includes an anti-MAGE-A4 single-chain variable fragment (scFv) domain, and the anti-MAGE-A4 scFv domain includes a light chain variable region (LCVR) and a heavy chain variable region (HCVR). In some embodiments, the anti-MAGE-A4 scFv domain comprises a first linker between the LCVR and the HCVR. In some embodiments, the MAGE-A4 specific CAR further comprises a second linker between the extracellular ligand binding domain and the hinge. In some embodiments, the first linker and the second linker comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 23-26. In some embodiments, the first linker comprises an amino acid sequence of SEQ ID NO: 25, and the second linker comprises an amino acid sequence of SEQ ID NO: 23.
[0014] In some embodiments, the hinge, transmembrane domain, or both of the MAGE-A4 specific CAR are from a CD8α polypeptide. In some embodiments, the costimulatory domain comprises a 4-1BB costimulatory domain. In some embodiments, the hinge, the transmembrane domain, or both are from a CD28 polypeptide. In some embodiments, the costimulatory domain comprises a CD28 costimulatory domain. In some embodiments, the signaling domain comprises a CD3ζ signaling domain. In some embodiments, the LCVR comprises a complementary determining region (CDR) of a LCVR comprising an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 37. In some embodiments, the LCVR comprises LCDR1-LCDR2-LCDR3, and the LCDR1-LCDR2-LCDR3 comprises an amino acid sequence of SEQ ID NO: 12-14-16, respectively. In some embodiments, the HCVR comprises a CDR of a HCVR comprising an amino acid sequence of SEQ ID NO: 2. In some embodiments, the HCVR comprises HCDR1-HCDR2-HCDR3, and the HCDR1-HCDR2-HCDR3 comprises an amino acid sequence of SEQ ID NO: 4-6-8, respectively.
[0015] In some embodiments, the MAGE-A4 specific CAR comprises a LCVR comprising an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 37 or an amino acid sequence having 95% to 99% sequence identity to an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 37; and a HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2 or an amino acid sequence having 95% to 99% sequence identity to an amino acid sequence of SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 37, and the HCVR comprises an amino acid sequence of SEQ ID NO: 2. In some embodiments, the LCVR comprises a complementary determining region (CDR) of a LCVR comprising an amino acid sequence of SEQ ID NO: 59. In some embodiments, the LCVR comprises LCDR1-LCDR2-LCDR3, and the LCDR1-LCDR2-LCDR3 comprises an amino acid sequence of SEQ ID NO: 61-63-65, respectively. In some embodiments, the HCVR comprises a CDR of a HCVR comprising an amino acid sequence of SEQ ID NO: 51. In some embodiments, the HCVR comprises HCDR1-HCDR2-HCDR3, and the HCDR1-HCDR2-HCDR3 comprises the amino acid sequences of SEQ ID NO: 53-55-57, respectively. In some embodiments, the MAGE-A4-specific CAR comprises a LCVR comprising an amino acid sequence of SEQ ID NO: 59 or an amino acid sequence having 95% to 99% sequence identity with the amino acid sequence of SEQ ID NO: 59; and a HCVR comprising an amino acid sequence of SEQ ID NO: 51 or an amino acid sequence having 95% to 99% sequence identity with the amino acid sequence of SEQ ID NO: 51. In some embodiments, the LCVR comprises an amino acid sequence of SEQ ID NO: 59, and the HCVR comprises an amino acid sequence of SEQ ID NO: 51. In some embodiments, the hinge comprises an amino acid sequence of SEQ ID NO: 27. In some embodiments, the transmembrane domain comprises an amino acid sequence of SEQ ID NO: 28. In some embodiments, the 4-1BB costimulatory domain comprises an amino acid sequence of SEQ ID NO: 29. In some embodiments, the hinge comprises an amino acid sequence of SEQ ID NO: 41. In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 43. In some embodiments, the CD28 costimulatory domain comprises the amino acid sequence of SEQ ID NO: 45.In some embodiments, the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 22. In some embodiments, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the MAGE-A4-specific CAR comprises the amino acid sequence of SEQ ID NO: 47. In some embodiments, the MAGE-A4-specific CAR comprises the amino acid sequence of SEQ ID NO: 71. In some embodiments, the MAGE-A4-specific CAR comprises the amino acid sequence of SEQ ID NO: 73. In some embodiments, the chimeric antigen receptor specifically binds to one or more amino acids at positions 286-294 of SEQ ID NO: 32. In some embodiments, the MAGE-A4-specific CAR specifically binds to one or more amino acids at positions 230-239 of SEQ ID NO: 32. In some embodiments, the HLA is HLA-A2.
[0016] On the one hand, the present disclosure provides an isolated nucleic acid molecule encoding a MAGE-A4-specific CAR as described herein. In some embodiments, the isolated nucleic acid molecule includes a nucleotide sequence of SEQ ID NO: 21. In some embodiments, the isolated nucleic acid molecule includes a nucleotide sequence of SEQ ID NO: 38. In some embodiments, the isolated nucleic acid molecule includes a nucleotide sequence of SEQ ID NO: 48. In some embodiments, the isolated nucleic acid molecule includes a nucleotide sequence of SEQ ID NO: 70. In some embodiments, the isolated nucleic acid molecule includes a nucleotide sequence of SEQ ID NO: 72. On the one hand, the present disclosure provides a vector including a nucleic acid molecule described herein. In some embodiments, the vector is a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector. In some embodiments, the vector is a lentiviral vector.
[0017] On the one hand, the present disclosure provides a cell comprising a nucleic acid molecule as described herein or a vector as described herein. In some embodiments, the cell is a human T cell. In some embodiments, the engineered cell comprises a chimeric antigen receptor as described herein. In some embodiments, the engineered cell is an immune cell such as an immune effector cell or a T lymphocyte (e.g., an inflammatory T lymphocyte, a cytotoxic T lymphocyte, a regulatory T lymphocyte, or a helper T lymphocyte). In some embodiments, the engineered cell is a CD8+ cytotoxic T lymphocyte. In some embodiments, the engineered cell is used to treat MAGE-A4 expressing cancers such as multiple myeloma or melanoma.
[0018] On the one hand, the present disclosure provides an engineered human T cell, comprising a chimeric antigen receptor, the chimeric antigen receptor comprising from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising an anti-MAGE-A4 single chain variable fragment (scFv) domain, the anti-MAGE-A4 scFv domain comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR); (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a 4-1BB co-stimulatory domain or a CD28 co-stimulatory domain and a CD3ζ signaling domain. In some embodiments, the anti-MAGE-A4 scFv specifically binds to one or more amino acid residues at positions 286-294 of SEQ ID NO: 32. In some embodiments, the scFv domain comprises an HCVR / LCVR amino acid sequence pair comprising an amino acid sequence of SEQ ID NO: 2 / 10. In some embodiments, the scFv domain comprises an HCVR / LCVR amino acid sequence pair comprising an amino acid sequence of SEQ ID NO: 2 / 37. In some embodiments, the scFv domain specifically binds to one or more amino acid residues at positions 230-239 of SEQ ID NO:32. In some embodiments, the scFv domain comprises a HCVR / LCVR amino acid sequence pair comprising the amino acid sequences of SEQ ID NO:51 / 59. In some embodiments, the hinge comprises the amino acid sequence of SEQ ID NO:27. In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO:28. In some embodiments, the 4-1BB co-stimulatory domain comprises the amino acid sequence of SEQ ID NO:29. In some embodiments, the hinge comprises the amino acid sequence of SEQ ID NO:41. In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO:43. In some embodiments, the CD28 co-stimulatory domain comprises the amino acid sequence of SEQ ID NO:45. In some embodiments, the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO:30. In some embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO:22. In some embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO:39. In some embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 71. In some embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 73.
[0019] In one aspect, the present disclosure provides a pharmaceutical composition comprising genetically modified human T cells and a pharmaceutically acceptable carrier, wherein the genetically modified human T cells comprise a chimeric antigen receptor as described herein. In some embodiments, the pharmaceutical composition comprises an engineered cell or engineered human T cell as described herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is used to treat MAGE-A4 expressing cancers such as multiple myeloma or melanoma.
[0020] In one aspect, the present disclosure provides a use of a chimeric antigen receptor as described herein, a nucleic acid molecule as described herein, a vector as described herein, a cell as described herein, an engineered cell as described herein, or an engineered human T cell as described herein in the manufacture of a medicament for treating a MAGE-A4-expressing cancer such as multiple myeloma or melanoma.
[0021] On the one hand, the present disclosure provides a method for enhancing the activity of T lymphocytes of a subject, the method comprising introducing a T lymphocyte comprising a chimeric antigen receptor as described herein into the subject. On the one hand, the present disclosure provides a method for treating a subject with cancer, the method comprising introducing a therapeutically effective amount of T lymphocytes comprising a chimeric antigen receptor as described herein into the subject. On the one hand, the present disclosure provides a method for stimulating a T cell-mediated immune response to a target cell population or tissue of a subject, the method comprising administering to the subject an effective amount of cells genetically modified to express a chimeric antigen receptor as described herein. On the one hand, the present disclosure provides a method for providing anti-tumor immunity in a subject, the method comprising administering to the subject an effective amount of cells genetically modified to express a chimeric antigen receptor as described herein. In some embodiments, the subject is a human. In some embodiments, the subject suffers from multiple myeloma, synovial sarcoma, esophageal cancer, head and neck cancer, lung cancer, bladder cancer, ovarian cancer, uterine cancer, gastric cancer, cervical cancer, breast cancer or melanoma. In some embodiments, the subject suffers from multiple myeloma.
[0022] In one aspect, the present disclosure provides a method for engineering a cell population to express a chimeric antigen receptor, the method comprising: (a) introducing a nucleic acid molecule encoding a chimeric antigen receptor as described herein into an immune cell population; (b) culturing the immune cell population under conditions expressing the nucleic acid molecule; and (c) isolating the cells expressing the chimeric antigen receptor at the surface of the immune cells. In some embodiments, the method further comprises obtaining the immune cell population from a subject before introducing the nucleic acid molecule.
[0023] In one aspect, the present disclosure provides a method of treating a subject's cancer expressing MAGE-A4, the method comprising: (a) engineering a cell population as described herein; and (b) reintroducing the cell population expressing the chimeric antigen receptor into the subject. In some embodiments, the MAGE-A4 expressing cancer is multiple myeloma.
[0024] On the one hand, the present disclosure provides an isolated antigen binding protein that competes for binding with a MAGE-A4 specific CAR as described herein. In some embodiments, the isolated antigen binding protein is a CAR. On the one hand, the present disclosure provides an isolated antigen binding protein that binds to the same epitope as the MAGE-A4 specific CAR as described herein. In some embodiments, the isolated antigen binding protein is a CAR.
[0025] In one aspect, the present disclosure provides an isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to a melanoma-associated antigen A4 (MAGE-A4) polypeptide, wherein the antibody has one or more of the following properties: (a) a concentration of less than about 10 -9 M; (b) after administration to an animal, exhibits increased survival of the animal compared to a comparable animal not subjected to said administration; and / or (c) comprises: (i) three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR), the HCVR comprising an amino acid sequence having at least about 90% sequence identity to the HCVR shown in Table 1; and (ii) three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR), the LCVR comprising an amino acid sequence having at least about 90% sequence identity to the LCVR shown in Table 1. In some embodiments, the MAGE-A4 polypeptide is an HLA-A2-binding MAGE-A4 polypeptide.
[0026] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a HCVR having an amino acid sequence of SEQ ID NO: 2. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a LCVR having an amino acid sequence of SEQ ID NO: 10. In some cases, the isolated antibody or antigen-binding fragment thereof comprises a HCVR / LCVR amino acid sequence pair of SEQ ID NO: 2 / 10. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a LCVR having an amino acid sequence of SEQ ID NO: 37. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a HCVR having an amino acid sequence of SEQ ID NO: 51. In some cases, the isolated antibody or antigen-binding fragment thereof comprises a HCVR / LCVR amino acid sequence pair of SEQ ID NO: 2 / 37.
[0027] In one aspect, the present disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising: (a) a HCDR1 domain having an amino acid sequence of SEQ ID NO: 4; (b) a HCDR2 domain having an amino acid sequence of SEQ ID NO: 6; (c) a HCDR3 domain having an amino acid sequence of SEQ ID NO: 8; (d) a LCDR1 domain having an amino acid sequence of SEQ ID NO: 12; (e) a LCDR2 domain having amino acid 14; and (f) a LCDR3 domain having an amino acid sequence of SEQ ID NO: 16.
[0028] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a LCVR having the amino acid sequence of SEQ ID NO:59.
[0029] In one aspect, the present disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising: (a) a HCDR1 domain having an amino acid sequence of SEQ ID NO: 53; (b) a HCDR2 domain having an amino acid sequence of SEQ ID NO: 55; (c) a HCDR3 domain having an amino acid sequence of SEQ ID NO: 57; (d) a LCDR1 domain having an amino acid sequence of SEQ ID NO: 61; (e) a LCDR2 domain having an amino acid sequence of SEQ ID NO: 63; and (f) a LCDR3 domain having an amino acid sequence of SEQ ID NO: 65.
[0030] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises the HCVR / LCVR amino acid sequence pair of SEQ ID NO:51 / 59.
[0031] In some embodiments, the isolated antibody or antigen-binding fragment thereof is an IgG1 antibody. In some embodiments, the isolated antibody or antigen-binding fragment thereof is an IgG4 antibody. In some embodiments, the isolated antibody or antigen-binding fragment thereof is a bispecific antibody.
[0032] On the one hand, the present disclosure provides a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof as discussed above or herein and a pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutical composition further comprises a second therapeutic agent. In some cases, the second therapeutic agent is selected from the group consisting of: an anti-tumor agent, a steroid, and a targeted therapy.
[0033] In one aspect, the present disclosure provides a polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR or LCVR of an antibody as discussed above or herein.
[0034] In one aspect, the present disclosure provides a vector comprising the polynucleotide discussed above.
[0035] In one aspect, the present disclosure provides a cell comprising the vector discussed above.
[0036] In one aspect, the present disclosure provides a method of treating a MAGE-A4 expressing cancer, wherein the method comprises administering to a subject an antibody or antigen binding fragment or pharmaceutical composition as discussed above or herein. In some embodiments, the pharmaceutical composition is administered in combination with a second therapeutic agent. In some cases, the second therapeutic agent is selected from the group consisting of an anti-tumor agent, a steroid, and a targeted therapy. The use of antibodies, antigen binding fragments thereof, and pharmaceutical compositions for treating a MAGE-A4 expressing cancer or in the manufacture of a medicament for treating a MAGE-A4 expressing cancer is also contemplated within the scope of the present disclosure.
[0037] Other embodiments will become apparent upon reading the ensuing detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 Exemplary nucleotide constructs for expressing chimeric antigen receptor (CAR) constructs are shown. Exemplary nucleotide constructs include anti-MAGE-A4 VL-linker-VH scFv, human CD8 hinge and transmembrane domains, 4-1BB costimulatory domains, CD3ζ signaling domains, and IRES:eGFP sequences for tracking CAR-transduced cells.
[0039] Figure 2A and Figure 2B : Figure 2ADepicted are in vitro cytotoxicity data showing that HLA-A2 / MAGE-A4 compared to control CAR T cells against A375 cells (A375 and A375++ can be seen as the top two curves depicted). 286-294 Targeted CAR T cells against A375 human melanoma tumor cells (open black circles, dashed lines) and overexpressing HLA-A2 / MAGE-A4 286-294 A375 cells (solid black circles, solid line, denoted as A375++) exhibited enhanced cytotoxicity. Figure 2B Depicted are in vitro cytotoxicity data showing that HLA-A2 / MAGE-A4 compared to control CAR T cells on A375 cells (IM9 and IM9++ can be seen as the top two curves depicted). 286-294 Targeted CAR T cells against IM9 multiple myeloma cells (open black circles, dotted lines) and cells that overexpress HLA-A2 / MAGE-A4 286-294 IM9 cells of the target cells (solid black circles, solid line, denoted as IM9++) exhibited enhanced cytotoxicity.
[0040] Figure 3A and Figure 3B : Figure 3A Depicted are the HLA-A2 / HPV16E7 (11-19) CAR T cells treated with control CAR T cells (anti-HLA-A2 / HPV16E7 (11-19) CAR T cells). + MAGE-A4 + Tumor volume over time in mice bearing A375 human melanoma tumor cell xenografts. Of the five mice tested, none were tumor-free at the end of the study (animals were euthanized on day 42). Figure 3B Depicts the use of anti-HLA-A2 / MAGE-A4 286-294 CAR T cells treated with HLA-A2 + MAGE-A4 + Tumor volume over time in mice bearing A375 human melanoma tumor cell xenografts. At the end of the study (day 55), all five mice tested were tumor-free.
[0041] Figure 4A and Figure 4B : Figure 4A Depicted are the HLA-A2 / HPV16E7 (11-19) CAR T cells treated with control CAR T cells (anti-HLA-A2 / HPV16E7 (11-19) CAR T cells). + MAGE-A4 +Tumor volume over time in mice bearing IM9 human multiple myeloma tumor cell xenografts. Of the five mice tested, none were tumor-free at the end of the study (animals were euthanized on day 29). Figure 4B Depicts the use of anti-HLA-A2 / MAGE-A4 286-294 CAR T cells treated with HLA-A2 + MAGE-A4 + Tumor volume over time in mice bearing IM9 human multiple myeloma tumor cell xenografts. Of the five mice tested, three were tumor-free at the end of the study (day 52). DETAILED DESCRIPTION
[0042] It should be understood that the invention described herein is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to be restrictive, because the scope of the present invention will be limited only by the appended claims. The features of any embodiment or embodiment can be combined with each other, and such combinations are clearly included in the scope of the present invention. Any specific value discussed above or herein can be combined with another related value discussed above or herein to list the range of values with the upper and lower ends of the representation range, and such ranges are included in the scope of the present disclosure.
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. As used herein, when used to refer to a specific listed numerical value, the term "about" means that the numerical value may differ from the cited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0044] Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entirety.
[0045] definition
[0046] As used herein, the term "MAGE-A4" refers to melanoma-associated antigen A4. MAGE-A4 is an intracellular protein expressed by a variety of different tumor cells. As used herein, unless specified as being from a non-human species (e.g., "mouse MAGE-A4," "monkey MAGE-A4," etc.), "MAGE-A4" refers to human MAGE-A4 protein. Human MAGE-A4 protein has the amino acid sequence shown in SEQ ID NO:32 and the polynucleotide sequence of SEQ ID NO:31. Reference to a specific region of the MAGE-A4 polypeptide (e.g., MAGE-A4 286-294 or MAGE-A4 230-239) is with respect to SEQ ID NO:32. As used herein, the terms "MAGE-A4 286-294," "MAGE-A4 (286-294)" and "MAGEA4 286-294 ” can be used interchangeably. Similarly, the terms “MAGE-A4 230-239”, “MAGE-A4 (230-239)” and “MAGEA4 230-239 " can be used interchangeably. The polypeptide sequence of MAGE-A4 (286-294) (KVLEHVVRV) is given as SEQ ID NO: 33. The polypeptide sequence of MAGE-A4 (230-239) (GVYDGREHTV) is given as SEQ ID NO: 49.
[0047] As used herein, "antibodies that bind to MAGE-A4" or "anti-MAGE-A4 antibodies" include antibodies that specifically recognize MAGE-A4 and antigen-binding fragments thereof. In some embodiments, the antibody that binds to MAGE-A4 interacts with amino acids 286-294 of MAGE-A4 or amino acids 230-239 of MAGE-A4.
[0048] The terms "ligand binding domain" and "antigen binding domain" are used interchangeably herein and refer to the portion of a chimeric antigen receptor or corresponding antibody that specifically binds to a predetermined antigen (e.g., MAGE-A4). Reference to a "corresponding antibody" refers to the antibody from which the CDRs or variable regions (heavy chain variable region (abbreviated as HCVR or VH) and light chain variable region (abbreviated as LCVR or VL)) used in the chimeric antigen receptor are derived. For example, the chimeric antigen receptor construct discussed in the Examples comprises a scFv having variable regions derived from an anti-MAGE-A4 antibody. This anti-MAGE-A4 antibody is the "corresponding antibody" of the corresponding chimeric antigen receptor.
[0049] As used herein, the term "antibody" means any antigen binding molecule or molecular complex comprising at least one complementary determining region (CDR) that specifically binds or interacts with a specific antigen (e.g., MAGE-A4). In some embodiments, the antibody can bind to or interact with an MHC binding polypeptide such as an HLA binding polypeptide. In the context of the present disclosure, in some embodiments, the antibody can bind to an HLA-A2 binding polypeptide such as a MAGE-A4 polypeptide presented by HLA-A2 (e.g., MAGE-A4 286-294 or 230-239). The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and multimers thereof (e.g., IgM). The term "antibody" also includes immunoglobulin molecules consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain (abbreviated herein as HC) includes a heavy chain variable region (abbreviated herein as HCVR or V H ) and the heavy chain constant region. The heavy chain constant region consists of three domains C H 1. C H 2 and C H 3. Each light chain (abbreviated herein as LC) includes a light chain variable region (abbreviated herein as LCVR or V L ) and the light chain constant region. The light chain constant region consists of a domain (C L 1) You can set V H Area and V L The V domains are further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L It is composed of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the present disclosure, the FRs of the anti-MAGE-A4 antibody (or its antigen-binding portion) may be identical to human germline sequences, or may be natural or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0050] As used herein, the term "antibody" also includes the antigen binding fragment of a complete antibody molecule. As used herein, the term "antigen binding portion thereof", "antigen binding fragment" of an antibody, etc., include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein, which specifically binds to an antigen to form a complex. The antigen binding fragment of an antibody can be derived from a complete antibody molecule, for example, using any suitable standard technique, such as proteolytic digestion or involving manipulation and expression of DNA encoding variable and optionally constant domains of an antibody. Such DNA is known and / or is easy to obtain from, for example, commercial sources, DNA libraries (comprising, for example, phage-antibody libraries), or can be synthesized. DNA can be sequenced and manipulated by chemical methods or by molecular biological techniques, for example, one or more variable domains and / or constant domains are arranged into a suitable configuration, or codons are introduced, cysteine residues are produced, modified, added or deleted amino acids, etc.
[0051] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., isolated complementary determining regions (CDRs), such as CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variant IgNAR domains are also encompassed within the expression "antigen-binding fragment" as used herein.
[0052] The antigen-binding fragment of an antibody generally includes at least one variable domain. The variable domain can have any size or amino acid composition and generally includes at least one CDR adjacent to or within a frame with one or more framework sequences. L Domain-related V H In the antigen-binding fragment of the structural domain, V H and V L The domains may be positioned relative to each other in any suitable arrangement. For example, the variable region may be a dimer and contain V H -V H 、V H -V L or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a monomer V H or VL Structural domain.
[0053] In certain embodiments, the antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of an antibody of the present disclosure include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C L. In any configuration of variable and constant regions, including any of the exemplary configurations listed above, the variable domains and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which results in a flexible or semi-flexible connection between adjacent variable domains and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragments of the antibodies of the present disclosure may include homodimers or heterodimers (or other multimers) of any of the variable domain and constant domain configurations listed above, which are non-covalently associated (e.g., through one or more disulfide bonds) with each other and / or with one or more monomeric VH or VL domains.
[0054] In certain embodiments, the anti-MAGE-A4 antibody from which the antigen-binding fragment is derived is a human antibody. As used herein, the term "human antibody" is intended to include antibodies having variable regions and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the present disclosure may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo), such as in CDRs, and specifically CDR3. However, as used herein, the term "human antibody" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been transplanted onto human framework sequences.
[0055] In some embodiments, the antibody used to generate the anti-MAGE-A4 antigen-binding fragment can be a recombinant human antibody. As used herein, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a self-recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20: 6287-6295), or antibodies prepared, expressed, produced or isolated by any other means involving splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies undergo in vitro mutagenesis (or, when using animals with transgenic human Ig sequences, undergo in vivo somatic mutagenesis), and thus the V H Area and V L The amino acid sequence of the region is as follows: H Sequence and V LSequences that are related to, but may not naturally exist in vivo in the human antibody germline repertoire.
[0056] Human antibodies can exist in two forms related to hinge heterogeneity. In one form, the immunoglobulin molecule includes a stable four-chain construct of about 150-160 kDa, in which the dimer is held together by an interchain heavy chain disulfide bond. In the second form, the dimer is not connected by an interchain disulfide bond and forms a molecule of about 75-80 kDa, which is composed of covalently coupled light and heavy chains (half antibodies). Even after affinity purification, these forms are extremely difficult to separate.
[0057] The frequency of the second form in various intact IgG isotypes is based on, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the occurrence of the second form (Angal et al. (1993) Molecular Immunology 30:105) to the level typically observed with the human IgG1 hinge. The present disclosure contemplates substitutions in the hinge region, C H Zone 2 or C H Antibodies with one or more mutations in region 3, which may be desirable, for example, in production to increase the yield of a desired antibody form.
[0058] The antibody can be an isolated antibody. As used herein, an "isolated antibody" means an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an "isolated antibody" for purposes of the present disclosure. Isolated antibodies also include antibodies in situ within recombinant cells. An isolated antibody is an antibody that has been subjected to at least one purification or separation step. According to certain embodiments, the isolated antibody may be substantially free of other cellular material and / or chemicals.
[0059] As compared to the corresponding germline sequence of the derived antibody, the anti-MAGE-A4 antibody or antigen-binding fragment thereof disclosed herein may include one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains. Such mutations can be easily determined by comparing the amino acid sequences disclosed herein with germline sequences that can be obtained from, for example, public antibody sequence databases. The present disclosure includes antibodies and antigen-binding fragments thereof derived from any amino acid sequence disclosed herein, wherein one or more amino acids in one or more framework and / or CDR regions are mutated to one or more corresponding residues of the germline sequence of the derived antibody, or mutated to one or more corresponding residues of another human germline sequence, or mutated to conservative amino acid substitutions of one or more corresponding germline residues (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, a person of ordinary skill in the art can easily generate many antibodies and antigen-binding fragments including one or more individual germline mutations or combinations thereof. In certain embodiments, all framework and / or CDR residues in the VH domain and / or VL domain are mutated back to the residues found in the original germline sequence of the derived antibody. In other embodiments, only certain residues are mutated back to the original germline sequence, for example, only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found in CDR1, CDR2 or CDR3. In other embodiments, one or more of one or more framework and / or CDR residues are mutated to one or more corresponding residues of different germline sequences (i.e., germline sequences different from the germline sequences from which the antibody was originally derived). Further, the antibodies of the present disclosure may contain any combination of two or more germline mutations within the framework and / or CDR regions, for example, wherein certain individual residues are mutated to corresponding residues of a specific germline sequence, while certain other residues different from the original germline sequence may be maintained or mutated to corresponding residues of different germline sequences. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations may be easily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or exciting biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed by the present disclosure.
[0060] The anti-MAGE-A4 antibody may include a variant of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the anti-MAGE-A4 antibody may have a HCVR, LCVR and / or CDR amino acid sequence having, for example, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 conservative amino acid substitution relative to any of the HCVR, LCVR and / or CDR amino acid sequences set forth herein.
[0061] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule called a paratope. A single antigen can have more than one epitope. Therefore, different antibodies can bind to different regions on the antigen and can have different biological effects. Epitopes can be conformational or linear. Conformational epitopes are produced by spatial juxtaposition of amino acids from different segments of a linear polypeptide chain. Linear epitopes are epitopes produced by adjacent amino acid residues in a polypeptide chain. In some cases, an epitope can contain a portion of a sugar, phosphoryl, or sulfonyl group on the antigen.
[0062] The term "substantial identity" or "substantially identical" when referring to a nucleic acid or a fragment thereof means a nucleotide sequence identity of at least about 95%, more preferably at least about 96%, 97%, 98% or 99% of the nucleotide bases when optimally aligned with another nucleic acid (or its complementary strand) by appropriate nucleotide insertions or deletions, as measured by any well-known sequence identity algorithm such as FASTA, BLAST or Gap, as discussed below. In some cases, a nucleic acid molecule having substantial identity to a reference nucleic acid molecule can encode a polypeptide having an amino acid sequence that is identical or substantially similar to a polypeptide encoded by the reference nucleic acid molecule. In some embodiments, the present disclosure provides a polypeptide comprising a sequence that is at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9%, or 100% identical to the sequence of SEQ ID NO:22 or SEQ ID NO:39, or to a portion of SEQ ID NO:22 or SEQ ID NO:39 (e.g., a HCVR such as the sequence of SEQ ID NO:2 or a HCVR such as the sequence of SEQ ID NO:10 or SEQ ID In some embodiments, the present disclosure provides a polynucleic acid encoding such a polypeptide.In some embodiments, the present disclosure provides a polynucleic acid comprising a sequence that is at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9%, or 100% identical to the sequence of SEQ ID NO: 21 or SEQ ID NO: 38, or to a portion of SEQ ID NO: 21 or SEQ ID NO: 38 (e.g., a HCVR such as the sequence of SEQ ID NO: 1 or a HCVR such as the sequence of SEQ ID NO: 9 or SEQ ID NO:36 or the framework region of a polynucleotide sequence such as SEQ ID NO:1, 9, 21, 36 or 38).
[0063] When applied to these polypeptides, the term "substantial similarity" or "substantially similar" means that two peptide sequences share at least 95% sequence identity, even more preferably at least 98% or 99% sequence identity when optimally aligned using the default gap weights by the programs GAP or BESTFIT. Preferably, the residue positions that are not identical differ by conservative amino acid substitutions. "Conservative amino acid substitutions" are amino acid substitutions in which an amino acid residue is substituted by another amino acid residue having a similar side chain (R group) with chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions do not substantially change the functional properties of proteins. In the case where two or more amino acid sequences differ from each other due to conservative substitutions, the sequence identity percentage or degree of similarity can be adjusted upward to correct the conservative nature of the substitution. Methods for making this adjustment are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference. Examples of amino acid groups having side chains with similar chemical properties include (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid, and (7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acid substitutions are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., (1992), Science, 256: 1443-1445, incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
[0064] Sequence similarity of polypeptides also referred to as sequence identity is usually measured using sequence analysis software. Protein analysis software uses measurements assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions to match similar sequences. For example, the tool GCG contains programs such as Gap and Bestfit, which can be used under default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as between homologous polypeptides from different organism species or between wild-type proteins and their mutant proteins. See, for example, version 6.1 GCG. FASTA using default or recommended parameters can also be used to compare polypeptide sequences, which is a program in version 6.1 GCG. FASTA (e.g., FASTA2 and FASTA3) provides alignment and sequence identity percentage of the best overlapping region between the query sequence and the search sequence (Pearson (2000), supra). Sequences can also be compared using the Smith-Waterman homology search algorithm, which uses an affine gap search with a gap open penalty of 12, and a gap extension penalty of 2, and a BLOSUM matrix of 62. When comparing the sequences of the present disclosure to databases containing a large number of sequences from different organisms, another preferred algorithm is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Research 25:3389-402, each of which is incorporated herein by reference.
[0065] As used herein, the term "nucleic acid" or "polynucleotide" refers to nucleotides and / or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by polymerase chain reaction (PCR), and fragments generated by any one of connection, rupture, endonuclease action and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally occurring nucleotides (such as DNA and RNA) or analogs of naturally occurring nucleotides (for example, enantiomeric forms of naturally occurring nucleotides) or a combination of the two. Modified nucleotides can have changes in the sugar moiety and / or in the pyrimidine or purine base moiety. Sugar modifications include, for example, replacement of one or more hydroxyls with halogens, alkyls, amines and azidos, or sugars can be functionalized as ethers or esters. In addition, the entire sugar moiety can be replaced by spatial and electronically similar structures (such as azasugars and carbocyclic sugar analogs). Examples of modifications in the base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines or other well-known heterocyclic substituents. Nucleic acid monomers can be connected by phosphodiester bonds or analogs of such connections. Nucleic acids can be single-stranded or double-stranded.
[0066] The term "chimeric antigen receptor" (CAR) refers to a molecule that combines binding domains for components present on target cells, such as antibody-based specificity for a desired antigen (e.g., tumor antigens such as MAGE-A4), which has a T cell receptor activating intracellular domain to generate a chimeric protein that exhibits specific anti-target cell immune activity. Typically, CAR consists of an extracellular single-chain antibody binding domain (scFv) fused to the intracellular signaling domain of the ζ chain of the T cell antigen receptor complex, and when expressed in T cells, has the ability to specifically redirect antigen recognition based on monoclonal antibodies.
[0067] The term "HLA" refers to the human leukocyte antigen (HLA) system or complex, which is a complex of genes encoding a person's major histocompatibility complex (MHC) proteins. These cell surface proteins are responsible for regulating a person's immune system. HLAs corresponding to class I MHC (A, B, and C) present peptides from within the cell.
[0068] The term "HLA-A" refers to the group of human leukocyte antigens (HLA) encoded by the HLA-A locus. HLA-A is one of the three main types of class I human MHC cell surface receptors. The receptor is a heterodimer and consists of a heavy alpha chain and a smaller beta chain. The alpha chain is encoded by a variant HLA-A gene, and the beta chain (beta2-microglobulin) is the invariant beta2 microglobulin molecule.
[0069] The term "HLA-A2" refers to a specific class I major histocompatibility complex (MHC) allele group at the HLA-A locus; the alpha chain is * The β chain is encoded by the β2-microglobulin or B2M locus.
[0070] As used herein, the term "vector" includes but is not limited to viral vectors, plasmids, RNA vectors or linear or circular DNA or RNA molecules, which can be composed of chromosomes, non-chromosomes, semi-synthetic or synthetic nucleic acids. In some cases, vectors are those capable of autonomous replication (episomal vectors) and / or expression of nucleic acids (expression vectors) connected thereto. A large number of suitable vectors are known to those skilled in the art and are commercially available. Viral vectors include retroviruses, adenoviruses, parvoviruses (e.g., adeno-associated viruses), coronaviruses, negative-strand RNA viruses such as orthomyxoviruses (e.g., influenza viruses), rhabdoviruses (e.g., rabies and vesicular stomatitis viruses), paramyxoviruses (e.g., measles and Sendai), positive-strand RNA viruses such as picornaviruses and alphaviruses, and double-stranded DNA viruses, including adenoviruses, herpesviruses (e.g., herpes simplex virus type 1 and type 2, Epstein-Barr virus (Epstein-Barr virus), cytomegalovirus) and poxviruses (e.g., vaccinia, fowlpox and canarypox). Other viruses include, for example, Norwalk virus, togavirus, flavivirus, reovirus, papovavirus, hepadnavirus and hepatitis virus. Examples of retroviruses include: avian leukosis sarcoma, mammalian C-type, B-type virus, D-type virus, HTLV-BLV group and lentivirus.
[0071] "Costimulatory domain" or "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response of the cell, such as but not limited to proliferation. Costimulatory molecules include but are not limited to MHC class I molecules, BTLA and Toll ligand receptors. Examples of costimulatory molecules include CD27, CD28, CD8, 4-1BB (CD137) (SEQ ID NO: 29), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds to CD83, etc. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands, which are necessary for an effective immune response.
[0072] "Co-stimulatory ligand" refers to a molecule on an antigen presenting cell that specifically binds to a cognate co-stimulatory molecule on a T cell, thereby providing a signal in addition to the primary signal provided by, for example, the binding of a TCR / CD3 complex to an MHC molecule loaded with a peptide, which mediates T cell responses, including but not limited to proliferation activation, differentiation, etc. Co-stimulatory ligands may include but are not limited to CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible co-stimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, agonists or antibodies that bind to Toll ligand receptors, and ligands that specifically bind to B7-H3.
[0073] A "co-stimulatory signal" refers to a signal that, in combination with a primary signal such as TCR / CD3 ligation, results in T cell proliferation and / or up- or down-regulation of key molecules.
[0074] As used herein, the term "extracellular ligand binding domain" refers to an oligonucleotide or polypeptide capable of binding a ligand, such as a cell surface molecule. For example, the extracellular ligand binding domain can be selected to recognize a ligand that acts as a cell surface marker on a target cell associated with a particular disease state (e.g., cancer). Examples of cell surface markers that can serve as ligands include those associated with viral, bacterial and parasitic infections, autoimmune diseases, and cancer cells. The extracellular ligand binding domain can include LCVR and HCVR regions (e.g., formatted as scFv), optionally connected by a linker.
[0075] As used herein, the term "subject" or "patient" includes all members of the animal kingdom, including non-human primates and humans. In one embodiment, the patient is a human suffering from cancer (eg, multiple myeloma or melanoma).
[0076] As used herein, the "signal transduction domain" or "signaling domain" of CAR is responsible for intracellular signal transduction after the extracellular ligand binding domain binds to the target, resulting in the activation of immune cells and immune responses. In other words, the signal transduction domain is responsible for activating at least one of the normal effector functions of the immune cells expressing CAR. For example, the effector function of T cells can be cytolytic activity or auxiliary activity (including the secretion of cytokines). Therefore, the term "signaling domain" refers to a part of a protein that transduces effector function signals and guides cells to perform specialized functions. Examples of signal transduction domains for use in CAR can be cytoplasmic sequences of T cell receptors and co-receptors that synergize after antigen receptor binding to initiate signal transduction, as well as any derivatives or variants of these sequences and any synthetic sequences with the same functional capabilities. In some cases, the intracellular signaling domain includes two different types of cytoplasmic signaling sequences: cytoplasmic signaling sequences that initiate antigen-dependent primary activation, and cytoplasmic signaling sequences that act in an antigen-independent manner to provide secondary or costimulatory signals. The primary cytoplasmic signaling sequence may include a signaling motif, which is referred to as an immunoreceptor tyrosine activation motif ITAM. ITAM is a well-defined signaling motif found in the cytoplasmic tail of various receptors, which acts as a binding site for syk / zap70 class tyrosine kinases. Exemplary ITAMs include those derived from TCR ζ, FcRγ, FcRβ, FcRε, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d. In some embodiments, the signal transduction domain of CAR may include a CD3ζ signaling domain (SEQ ID NO: 30).
[0077] Chimeric Antigen Receptor (CAR)
[0078] Chimeric antigen receptors (CARs) can redirect T cells specifically toward antigens recognized by antibodies on the surface of cells (e.g., cancer cells), whether those antigens are expressed on the cell surface or expressed intracellularly and presented by, for example, HLA.
[0079] One aspect of the present disclosure includes a chimeric antigen receptor (CAR) that is specific for MAGE-A4 antigens presented on the surface of cells such as tumor cells. For example, this presentation can be performed by HLAs such as HLA-A2, for example. In one embodiment of the present disclosure, the CAR as described herein includes an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (such as a signaling domain derived from CD3ζ or FcRγ), and / or one or more costimulatory signaling domains derived from costimulatory molecules, such as but not limited to 4-1BB. In one embodiment, CAR includes a hinge or spacer between an extracellular binding domain and a transmembrane domain, such as a CD8α hinge.
[0080] The binding domain or extracellular domain of CAR provides CAR with the ability to bind to the target antigen of interest. The binding domain (e.g., ligand binding domain or antigen binding domain) can be any protein, polypeptide, oligopeptide or peptide with the ability to specifically recognize and bind biomolecules (e.g., cell surface receptors or tumor proteins or components thereof). The binding domain includes any naturally occurring, synthetic, semi-synthetic or recombinantly produced binding partners of the biomolecule of interest. For example, and as further described herein, the binding domain can be an antibody light chain and heavy chain variable region, or the light chain and heavy chain variable region can be connected together with a single chain and any orientation (e.g., VL-VH or VH-VL). It is known to identify a variety of determinations of the binding domain of the present disclosure specifically bound to a specific target, including Western blotting, ELISA, flow cytometry or surface plasmon resonance analysis (e.g., using BIACORE analysis). The target can be a clinically concerned antigen, and it is expected that the effector immune response that causes tumor killing is triggered for the antigen. In one embodiment, the target antigen of the binding domain of the chimeric antigen receptor is a MAGE-A4 protein on the surface of a tumor cell (eg, an HLA-presented MAGE-A4 protein such as an HLA-A2-presented MAGE-A4 protein).
[0081] Illustrative ligand binding domains include antigen binding proteins such as antigen binding fragments of antibodies, such as scFv, scTCR, the extracellular domain of receptors, ligands of cell surface molecules / receptors or their receptor binding domains, and tumor binding proteins. In certain embodiments, the antigen binding domains included in the CAR of the present disclosure can be variable regions (Fv), CDR, Fab, scFv, VH, VL, domain antibody variants (dAb), camel antibodies (VHH), fibronectin 3 domain variants, ankyrin repeat variants and other antigen-specific binding domains derived from other protein scaffolds.
[0082] In one embodiment, the binding domain of CAR is an anti-MAGE-A4 single-chain antibody (scFv), and may be a mouse, human or humanized scFv. Single-chain antibodies can be cloned from the V region genes of hybridomas with specificity for the desired target. The technology that can be used to clone the variable region heavy chain (VH) and variable region light chain (VL) has been described in, for example, Orlandi et al., Proceedings of the National Academy of Sciences (PNAS), 1989; 86: 3833-3837. Therefore, in certain embodiments, the binding domain includes an antibody-derived binding domain but may be a non-antibody-derived binding domain. The antibody-derived binding domain may be a fragment of an antibody or a genetically engineered product of one or more fragments of an antibody, the fragment being related to binding to an antigen.
[0083] In certain embodiments, the CAR of the present disclosure may include a joint between different domains, adding appropriate spacing and conformation for the molecule. For example, in one embodiment, there may be a joint between the binding domain VH or VL, and the length of the joint may be between 1 and 20 amino acids. In other embodiments, the length of the joint between any domain in the domain of the chimeric antigen receptor may be between 1 and 15 amino acids or 15 amino acids. In this regard, the length of the joint may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. In another embodiment, the length of the joint may be 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. The range of numbers described herein is also included herein, such as 10 to 30 amino acid long joints.
[0084] In certain embodiments, the joint suitable for CAR described herein is a flexible joint. Suitable joints can be easily selected, and can be with such as 1 amino acid (for example, Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids or 7 amino acids to 8 amino acids and other suitable joints of different lengths any one, and can be 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids or 7 amino acids.
[0085] Exemplary flexible linkers include glycine polymers (G) n, glycine-serine polymers (where n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore can act as neutral tethers between domains of fusion proteins such as CAR as described herein. Glycine obtains significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, "Review of Computational Chemistry (Rev. Computational Chem.)" 11173-142 (1992)). Ordinary technicians will recognize that the design of CAR can include fully or partially flexible linkers, so that the linker can include a flexible linker and one or more parts that impart less flexible structure to provide the desired CAR structure. Specific linkers include (G4S) n A linker, wherein n=1-3, as shown in SEQ ID NO: 23-25. Another exemplary linker is provided as SEQ ID NO: 26. The linker may be present between the LCVR region and the HCVR region of the CAR, between the variable region (such as the HCVR) and the hinge region (such as the CD8α hinge), or between the two. For example, the present disclosure provides a CAR comprising a (G4S) 3 linker between the LCVR and the HCVR and a (G4S) 1 linker between the HCVR and the CD8α hinge.
[0086] The binding domain of CAR may be followed by a "spacer" or "hinge", which refers to a region (Patel et al., Gene Therapy, 1999; 6: 412-419) that moves the antigen binding domain away from the effector cell surface to achieve appropriate cell / cell contact, antigen binding and activation. The hinge region in CAR is generally located between the transmembrane (TM) and the binding domain. In certain embodiments, the hinge region is an immunoglobulin hinge region, and may be a wild-type immunoglobulin hinge region or an altered wild-type immunoglobulin hinge region. Other exemplary hinge regions used in CAR described herein include hinge regions derived from the extracellular region of type 1 membrane proteins such as CD8α, CD4, CD28 and CD7, which may be wild-type hinge regions from these molecules or may be altered. In one embodiment, the hinge region includes a CD8α hinge (SEQ ID NO: 27).
[0087] "Transmembrane" region or domain is to anchor the extracellular binding part to the plasma membrane of immune effector cells, and promote the CAR part that binds to the target antigen. The transmembrane domain can be a CD3ζ transmembrane domain, but other transmembrane domains that can be used include those obtained from CD8α, CD4, CD28, CD45, CD9, CD16, CD22, CD33, CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain is the transmembrane domain of CD137. In some embodiments, the transmembrane domain includes SEQ ID NO:28 amino acid sequence. In certain embodiments, the transmembrane domain is synthetic, in which case the transmembrane domain will mainly include hydrophobic residues such as leucine and valine.
[0088] "Intracellular signaling domain" or "signaling domain" refers to a portion of a chimeric antigen receptor protein that is involved in transducing information about effective CAR binding to a target antigen to the interior of an immune effector cell to elicit effector cell functions, e.g., activation, cytokine production, proliferation, and cytotoxic activity, including the release of cytotoxic factors to CAR-bound target cells or other cellular responses elicited by antigen binding to an extracellular CAR domain. The term "effector function" refers to a specialized function of a cell. The effector function of a T cell may be, for example, cytolytic activity or auxiliary activity, including the secretion of cytokines. Therefore, the terms "intracellular signaling domain" or "signaling domain" used interchangeably herein refer to a portion of a protein that transduces effector function signals and directs cells to perform specialized functions. Although the entire intracellular signaling domain can generally be employed, the entire domain does not have to be used in many cases. To the extent that a truncated portion of an intracellular signaling domain is used, such a truncated portion may be used instead of the entire domain, as long as it transduces an effector function signal. The term intracellular signaling domain is intended to include any truncated portion of the intracellular signaling domain that is sufficient to transduce an effector function signal. The intracellular signaling domain is also referred to as a "signaling domain" and is typically derived from a portion of a human CD3 or FcRy chain.
[0089] It is known that the signal generated by the T cell receptor alone is not sufficient to fully activate T cells, and secondary or costimulatory signals are also required. Therefore, T cell activation can be said to be mediated by two different categories of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the T cell receptor (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences). Cytoplasmic signaling sequences that act in a costimulatory manner can contain signaling motifs known as immunoreceptor tyrosine-based activation motifs or ITAMs.
[0090] Examples of ITAMs containing primary cytoplasmic signaling sequences with particular use in the present disclosure include those derived from TCR ζ, FcR γ, FcR β, CD3 γ, CD3 δ, CD3 ε, CD5, CD22, CD79a, CD79b, and CD66d. In a specific embodiment, the intracellular signaling domain of the anti-MAGE-A4 CAR described herein is derived from CD3 ζ. In some embodiments, the signaling domain includes the amino acid sequence of SEQ ID NO: 30.
[0091] As used herein, the term "costimulatory signaling domain" or "costimulatory domain" refers to a CAR portion of an intracellular domain including a costimulatory molecule. Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors, which provide a second signal required for effective activation and T lymphocyte function after binding to an antigen. Examples of such costimulatory molecules include CD27, CD28, 4-1BB (CD137), OX40 (CD134), CD30, CD40, PD-1, ICOS (CD278), LFA-1, CD2, CD7, LIGHT, NKD2C, B7-H2, and a ligand specifically binding CD83. Therefore, although the present disclosure provides exemplary costimulatory domains derived from CD3ζ and 4-1BB, other costimulatory domains are contemplated for use with CAR described herein. The inclusion of one or more costimulatory signaling domains can enhance the efficacy and amplification of T cells expressing CAR receptors. The intracellular signaling domain and the costimulatory signaling domain can be connected in tandem to the carboxyl terminus of the transmembrane domain in any order. In some embodiments, the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 29.
[0092] Although scFv-based CARs engineered to contain signaling domains from CD3 or FcRγ have been shown to deliver potent signals for T cell activation and effector function, they are insufficient to elicit signals that promote T cell survival and expansion in the absence of concomitant co-stimulatory signals. Other CARs containing a binding domain, a hinge, a transmembrane and a signaling domain derived from CD3ζ or FcRγ and one or more co-stimulatory signaling domains (e.g., intracellular co-stimulatory domains derived from CD28, CD137, CD134, and CD278) can more effectively direct anti-tumor activity in vitro and in animal models and cancer patients as well as increase cytokine secretion, lytic activity, survival, and proliferation of CAR-expressing T cells (Milone et al., Molecular Therapy, 2009; 17: 1453-1464; Zhong et al., Molecular Therapy, 2010; 18: 413-420; Carpenito et al., Proc. Natl. Acad. Sci. USA, 2009; 106: 3360-3365).
[0093] In various embodiments, the anti-MAGE-A4 CAR of the present disclosure includes (a) an anti-MAGE-A4 scFv as a binding domain (e.g., an scFv having a binding region (e.g., CDR or variable domain) from an anti-MAGE-A4 antibody identified in Table 1); (b) a hinge region derived from human CD8α; (c) a human CD8α transmembrane domain and (d) a human T cell receptor CD3ζ chain (CD3) intracellular signaling domain, and optionally, one or more co-stimulatory signaling domains, such as 4-1BB. In one embodiment, the different protein domains are arranged from the amino terminus to the carboxyl terminus in the following order: a binding domain, a hinge region, and a transmembrane domain. The intracellular signaling domain and the optional co-stimulatory signaling domain are connected in series to the transmembrane carboxyl terminus in any order to form a single-chain chimeric polypeptide. In one embodiment, the nucleic acid construct encoding anti-MAGE-A4 CAR is a chimeric nucleic acid molecule including a nucleic acid molecule, and the nucleic acid molecule includes different coding sequences, such as (5' to 3') human anti-MAGE-A4 scFv, human CD8α hinge, human CD8α transmembrane domain and CD3ζ intracellular signaling domain coding sequence. In another embodiment, the nucleic acid construct encoding anti-MAGE-A4 CAR is a chimeric nucleic acid molecule including a nucleic acid molecule, and the nucleic acid molecule includes different coding sequences, such as (5' to 3') human anti-MAGE-A4 scFv, human CD8α hinge, human CD8α transmembrane domain, 4-1BB costimulatory domain and CD3ζ costimulatory domain coding sequence.
[0094] In certain embodiments, the polynucleotide encoding the CAR described herein is inserted into a vector. A vector is a medium into which a polynucleotide encoding a protein can be covalently inserted so as to cause expression of the protein and / or cloning of the polynucleotide. Such vectors may also be referred to as "expression vectors". The isolated polynucleotides may be inserted into a vector using any suitable method known in the art, such as, but not limited to, the vector may be digested with an appropriate restriction enzyme, and then it may be connected to an isolated polynucleotide having a matching restriction end. An expression vector may have the ability to incorporate and express a heterologous or modified nucleic acid sequence encoding at least a portion of a gene product that can be transcribed in a cell. In most cases, the RNA molecule is then translated into protein. An expression vector may contain a variety of control sequences, which refer to nucleic acid sequences necessary for transcription and possible translation of operably connected coding sequences in a specific host organism. In addition to control sequences for transcription and translation, vectors and expression vectors may also contain nucleic acid sequences with other functions, and are discussed below. An expression vector may include additional elements, for example, an expression vector may have two replication systems so that it is maintained in two organisms, such as expressed in human cells and cloned and amplified in a prokaryotic host.
[0095] The expression vector may have necessary 5' upstream and 3' downstream regulatory elements, such as promoter sequences (such as CMV, PGK and EF1α promoters), ribosome recognition and binding TATA box and 3'UTR AAUAAA transcription termination sequence, to carry out efficient gene transcription and translation in its corresponding host cell. Other suitable promoters include constitutive promoters of simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), HIV LTR promoter, MoMuLV promoter, avian leukosis virus promoter, EBV immediate early promoter and Rous sarcoma virus promoter. Human gene promoters may also be used, including but not limited to actin promoter, myosin promoter, hemoglobin promoter and creatine kinase promoter. In certain embodiments, inducible promoters are also considered to be part of the vector expressing the chimeric antigen receptor. This provides a molecular switch that can turn on or off the expression of the polynucleotide sequence of interest. Examples of inducible promoters include but are not limited to metallothionein promoters, glucocorticoid promoters, progesterone promoters or tetracycline promoters.
[0096] The expression vector may have other sequences, such as 6x-histidine, c-Myc and FLAG tags incorporated into the CAR expressed. Therefore, the expression vector may be engineered to contain 5' and 3' untranslated regulatory sequences, which may sometimes serve as enhancer sequences, promoter regions and / or terminator sequences for the efficient transcription of one or more nucleic acids of interest carried on the expression vector that may be promoted or enhanced. The expression vector may also be engineered for replication and / or expression function (e.g., transcription and translation) in specific cell types, cell positions or tissue types. The expression vector may include a selectable marker for maintaining a vector in a host or recipient cell.
[0097] In various embodiments, the vector is a plasmid, an autonomously replicating sequence, and a transposable element. Additional exemplary vectors include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs), phages such as lambda phage or M13 phage, and animal viruses. Examples of classifications of animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papovaviruses (e.g., SV40). Examples of expression vectors are Lenti-X for expression in mammalian cells. TM Bicistronic expression system (Neo) vector (Clontrch company), pClneo vector (Promega company (Promega)); pLenti4 / V5-DEST.TM, pLenti6 / V5-DEST.TM. and pLenti6.2N5-GW / lacZ (Invitrogen company (Invitrogen)) for lentiviral-mediated gene transfer and expression in mammalian cells. The coding sequence of CAR disclosed herein can be connected to such expression vectors to express chimeric proteins in mammalian cells.
[0098] In certain embodiments, nucleic acids encoding CARs of the present disclosure are provided in viral vectors. Viral vectors may be those derived from retroviruses, slow viruses or foamy viruses. As used herein, the term "viral vector" refers to a nucleic acid vector construct comprising at least one virally derived element and having the ability to be packaged into viral vector particles. The viral vector may contain coding sequences for various chimeric proteins described herein that replace non-essential viral genes. Vectors and / or particles may be used for the purpose of transferring DNA, RNA or other nucleic acids to cells in vitro or in vivo. Various forms of viral vectors are known in the art.
[0099] In certain embodiments, the viral vector containing the coding sequence of the CAR described herein is a retroviral vector or a lentiviral vector. The term "retroviral vector" refers to a vector containing structural and functional genetic elements mainly derived from retroviruses. The term "lentiviral vector" refers to a vector containing structural and functional genetic elements mainly derived from lentiviruses outside the LTR.
[0100] Retroviral vectors for use herein can be derived from any known retrovirus (e.g., type c retroviruses, such as Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), foamy virus, Friend virus (Friend), murine stem cell virus (MSCV) and Rous sarcoma virus (RSV)). The "retrovirus" of the present disclosure also includes human T-cell leukemia virus, HTLV-1 and HTLV-2, and the lentiviral family of retroviruses, such as human immunodeficiency virus, HIV-1, HIV-2, simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV) and other classes of retroviruses.
[0101] The lentiviral vector used herein refers to a vector derived from a lentivirus, a retroviral group (or genus) that causes a slowly developing disease. The viruses included in this group include HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); visna-maedi virus; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). The preparation of recombinant lentiviruses can be achieved using methods according to Dull et al. and Zufferey et al. (Dull et al., Journal of Virology (J. Virol), 1998; 72: 8463-8471 and Zufferey et al., Journal of Virology 1998; 72: 9873-9880).
[0102] Retroviral vectors (i.e., both lentiviral and non-lentiviral) for use in the present disclosure can be generated using standard cloning techniques by combining the desired DNA sequences in the order and orientation described herein (Current Protocols in Molecular Biology, Ausubel, FM et al. (eds.) Greene Publishing Associates, Inc., New York, NY). Associates), (1989), Sections 9.10-9.14 and other standard laboratory manuals; Eglitis et al. (1985), Science 230:1395-1398; Danos and Mulligan (1988) PNAS 85:6460-6464; Wilson et al. (1988) PNAS 85:3014-3018; Armentano et al. (1990) PNAS 87:6141-6145; Huber et al. (1991) PNAS 88:8039-8043; Ferry et al. (1991) PNAS 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol 150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT Application No. WO 89 / 07136; PCT Application No. WO 89 / 02468; PCT Application No. WO 89 / 05345; and PCT Application No. WO 92 / 07573).
[0103] Suitable sources for obtaining retroviral (i.e., lentiviral and non-lentiviral) sequences for use in forming vectors include, for example, genomic RNA and cDNA available from commercially available sources including the American Type Culture Collection (ATCC), Rockville, Md. The sequences may also be chemically synthesized.
[0104] In order to express MAGE-A4 CAR, the vector can be introduced into the host cell to allow the polypeptide to be expressed in the host cell. The expression vector may contain various elements for controlling expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selectable markers and signal sequences. As described herein, these elements may be appropriately selected by those of ordinary skill in the art. For example, a promoter sequence may be selected to promote transcription of polynucleotides in the vector. Suitable promoter sequences include but are not limited to T7 promoters, T3 promoters, SP6 promoters, β-actin promoters, EF1a promoters, CMV promoters and SV40 promoters. Enhancer sequences may be selected to enhance transcription of polynucleotides. Selectable markers may be selected to allow host cells to be selected from host cells without inserting the vector to insert the vector, for example, selectable markers may be genes that confer antibiotic resistance. Signal sequences may be selected to allow the expressed polypeptide to be transported outside the host cell.
[0105] In order to clone a polynucleotide, the vector can be introduced into a host cell (isolated host cell) to allow the vector to replicate itself, and thereby increase the copies of the polynucleotide contained therein. The cloning vector can contain sequence components, which generally include but are not limited to a replication origin, a promoter sequence, a transcription initiation sequence, an enhancer sequence, and a selectable marker. These elements can be appropriately selected by a person of ordinary skill in the art. For example, a replication origin can be selected to promote the autonomous replication of the vector in the host cell.
[0106] In certain embodiments, the disclosure provides a host cell containing the separation of the vector provided herein. The host cell containing the vector can be used for expressing or cloning the polynucleotide contained in the vector. Suitable host cells can include but are not limited to prokaryotic cells, fungal cells, yeast cells or higher eukaryotic cells, such as mammalian cells. Suitable prokaryotic cells for this purpose include but are not limited to true bacteria, such as Gram-negative or Gram-positive organisms, such as Enterobacteriaceae, such as Escherichia (Escherichia) (e.g., Escherichia coli (E.coli)), Enterobacter (Enterobacter), Erwinia (Erwinia), Klebsiella (Klebsiella), Proteus (Proteus), Salmonella (Salmonella) (e.g., Salmonella typhimurium (Salmonellatyphimurium)), Serratia (Serratia) (e.g., Serratia marcescens (Serratia marcescans) and Shigella; and Bacilli, such as B. subtilis and B. licheniformis; Pseudomonas, such as P. aeruginosa and Streptomyces.
[0107] The CAR of the present disclosure is introduced into a host cell using transfection and / or transduction techniques known in the art. As used herein, the terms "transfection" and "transduction" refer to the process of introducing an exogenous nucleic acid sequence into a host cell. Nucleic acids can be integrated into host cell DNA or can be maintained outside the chromosome. Nucleic acids can be transiently maintained or can be stably introduced. Transfection can be accomplished by various methods known in the art, including but not limited to calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and gene gun. Transduction refers to the use of a virus or retroviral vector to deliver one or more genes by viral infection rather than by transfection. In certain embodiments, a retroviral vector is transduced by packaging the vector into a virion before contacting the cell. For example, the nucleic acid encoding the anti-MAGE-A4CAR carried by the retroviral vector can be transduced into the cell by infection and proviral integration.
[0108] As used herein, the term "genetically engineered" or "genetically modified" refers to the addition of additional genetic material in the form of DNA or RNA to the total genetic material of a cell. The terms "genetically modified cell," "modified cell," and "redirected cell" are used interchangeably.
[0109] Specifically, the CARs of the present disclosure are introduced into immune effector cells and expressed in order to redirect their specificity to a target antigen of interest, such as a malignant MAGE-A4 expressing cell, such as a malignant cell presenting MAGE-A4 and HLA-A2.
[0110] The present disclosure provides a method for making immune effector cells expressing CAR as described herein. In one embodiment, the method includes transfection or transduction of immune effector cells separated from subjects such as subjects with MAGE-A4 expressive tumor cells, so that immune effector cells express one or more CARs as described herein. In certain embodiments, immune effector cells are separated from individuals and genetically modified without further manipulation in vitro. Then, such cells can be directly applied to individuals again. In other embodiments, immune effector cells are first activated and stimulated to proliferate in vitro before being genetically modified to express CAR. In this regard, immune effector cells can be cultured before or after being genetically modified (i.e., transduced or transfected to express CAR as described herein).
[0111] Prior to the in vitro manipulation or genetic modification of the immune effector cells described herein, a cell source can be obtained from a subject. Specifically, the immune effector cells used with the CAR described herein include T cells. T cells can be obtained from multiple sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumor. In certain embodiments, any number of techniques known to technicians (such as FICOLL separation) can be used to obtain T cells from the unit blood collected from the subject. In one embodiment, cells from the circulating blood of an individual are obtained by apheresis. Apheresis products generally contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, red blood cells and platelets. In one embodiment, cells collected by apheresis can be washed to remove the plasma portion and the cells are placed in a suitable buffer or culture medium for subsequent treatment. In one embodiment of the present disclosure, cells are washed with PBS. In alternative embodiments, the washing solution lacks calcium, and may lack magnesium, or may lack many (if not all) divalent cations. As will be appreciated by those of ordinary skill in the art, the washing steps can be accomplished by methods known to those of skill in the art, such as by using a semi-automatic flow-through centrifuge. After washing, the cells can be resuspended in various biocompatible buffers or other saline solutions with or without buffers. In certain embodiments, undesirable components of the apheresis sample can be removed in the medium in which the cells are directly resuspended.
[0112] In certain embodiments, the erythrocytes are lysed and the monocytes are depleted, for example, by using PERCOLL TM Gradient centrifugation is used to separate T cells from peripheral blood mononuclear cells (PBMC). Specific T cell subsets, such as CD28+, CD4+, CD8+, CD45RA+ and CD45RO+T cells, can be further separated by positive selection techniques or negative selection techniques. For example, the enrichment of T cell populations by negative selection can be completed by a combination of antibodies for surface markers specific to cells selected by negative selection. A method for use herein is to perform cell sorting and / or cell selection by negative magnetic immunoadhesion or flow cytometry using a mixture of monoclonal antibodies, and the monoclonal antibodies are directed to cell surface markers present on cells selected by negative selection. For example, in order to enrich CD4+ cells by negative selection, a monoclonal antibody mixture generally includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to separate the cell population of interest for use in the present disclosure.
[0113] Using methods as described herein, PBMC can be directly used for genetic modification with CAR. In certain embodiments, after the separation of PBMC, T lymphocytes are further separated, and in certain embodiments, cytotoxic and helper T lymphocytes can be classified into primary, memory and effector T cell subsets before or after genetic modification and / or amplification. CD8+ cells can be obtained by using standard methods. In certain embodiments, by identifying cell surface antigens associated with each of those types of CD8+ cells, CD8+ cells are further sorted into primary central memory cells and effector cells. In an embodiment, memory T cells are present in CD62L+ and CD62L- subgroups of CD8+ peripheral blood lymphocytes. PBMCs are sorted into CD62L-CD8+ and CD62L+CD8+ parts after staining with anti-CD8 and anti-CD62L antibodies. In certain embodiments, the expression of phenotypic markers of central memory TCM includes CD45RO, CD62L, CCR7, CD28, CD3 and CD127, and is negative for granzyme B. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some embodiments, naive CD8+ T lymphocytes are characterized by the expression of naive T cell phenotype markers including CD62L, CCR7, CD28, CD3, CD 127, and CD45RA.
[0114] In certain embodiments, CD4+T cells are further sorted into subgroups. For example, by identifying a cell population with a cell surface antigen, CD4+T helper cells can be sorted into primary central memory cells and effector cells. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, primary CD4+T lymphocytes are CD45RO-, CD45RA+, CD62L+CD4+T cells. In some embodiments, central memory CD4+ cells are CD62L positive and CD45RO positive. In some embodiments, effector CD4+ cells are CD62L and CD45RO negative.
[0115] Known methods can be used to genetically modify immune effector cells such as T cells after separation, or immune effector cells can be activated and amplified in vitro (or differentiated in the case of progenitor cells) before genetic modification. In another embodiment, immune effector cells such as T cells are genetically modified with chimeric antigen receptors as described herein (e.g., transduced with a viral vector including a nucleic acid encoding CAR) and then activated and amplified in vitro. Methods for activating and amplifying T cells are known in the art and are described in, for example, U.S. Patent No. 6,905,874; U.S. Patent No. 6,867,041; U.S. Patent No. 6,797,514; WO2012079000. Typically, such methods are included in a culture medium with appropriate cytokines such as IL-2, so that PBMC or separated T cells are contacted with stimulators and co-stimulators such as anti-CD3 and anti-CD28 antibodies that are generally connected to beads or other surfaces. Anti-CD3 and anti-CD28 antibodies connected to the same beads act as "replacement" antigen presenting cells (APC). In other embodiments, methods such as those described in: US Pat. No. 6,040,177; US Pat. No. 5,827,642; and WO2012129514 may be used to activate and stimulate T cells to proliferate with feeder cells and appropriate antibodies and cytokines.
[0116] The present disclosure provides a population of modified immune effector cells for use in treating a patient suffering from a malignancy arising from a MAGE-A4 expressing tumor, e.g., multiple myeloma or melanoma, the modified immune effector cells comprising an anti-MAGE-A4 CAR as disclosed herein.
[0117] CAR-expressing immune effector cells prepared as described herein can be used in methods and compositions of adoptive immunotherapy according to known techniques, or variations thereof apparent to those skilled in the art based on the present disclosure. See, for example, U.S. Patent Application Publication No. 2003 / 0170238 of Gruenberg et al.; see also U.S. Patent No. 4,690,915 of Rosenberg.
[0118] In some embodiments, cells are formulated by first harvesting the cells from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration in a therapeutically effective amount (a "pharmaceutically acceptable" carrier). Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott), or plasma-lysate A (Baxter), but 5% dextrose in water or Ringer's lactate can also be used. The infusion medium can be supplemented with human serum albumin.
[0119] The therapeutically effective amount of cells in the composition is at least 2 cells (e.g., at least 1 CD8+ central memory T cell and at least 1 CD4+ helper T cell subset) or more typically greater than 10 2 cells, and at most 10 6 Up to and including 10 8 or 10 9 cells, and can be more than 10 10 The number of cells will depend on the desired end use of the composition, as will the type of cells contained therein.
[0120] Cells can be autologous or allogeneic for patients undergoing therapy. If desired, treatment can also include administration of mitogens (e.g., PHA) or lymphokines, cytokines and / or chemokines (e.g., IFN-γ, IL-2, IL-12, TNF-α, IL-18 and TNF-β, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1α, etc.) as described herein to enhance the induction of immune response.
[0121] The CAR expressive immune effector cell group disclosed herein can be administered alone, or as a pharmaceutical composition and a diluent and / or in combination with other components such as IL-2 or other cytokines or cell groups. In short, the pharmaceutical composition disclosed herein may include a CAR expressive immune effector cell group as described herein, such as T cells, which are combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers such as neutral buffered saline, phosphate buffered saline, carbohydrates such as glucose, mannose, sucrose or dextran, mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), and preservatives. The composition disclosed herein is preferably formulated for intravenous administration.
[0122] The anti-tumor immune response induced in a subject by administering the CAR-expressing T cells described herein using the methods described herein or other methods known in the art may include a cellular immune response mediated by cytotoxic T cells, regulatory T cells, and helper T cell responses that can kill infected cells. A humoral immune response mediated mainly by helper T cells that can activate B cells to cause antibody production can also be induced. The type of immune response induced by the composition of the present invention can be analyzed using a variety of techniques described in detail in the art; for example, "Current Protocols in Immunology", edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober (2001) of John Wiley & Sons, New York, New York.
[0123] Thus, the present disclosure provides a method for treating an individual diagnosed with, suspected of having, or at risk of developing a malignancy characterized at least in part by expression of MAGE-A4 by cancer cells (e.g., MAGE-A4-expressing solid tumor cells), the method comprising administering to the individual a therapeutically effective amount of a CAR-expressing immune effector cell as described herein.
[0124] In one embodiment, the present disclosure provides a method of treating a subject diagnosed with a MAGE-A4-expressing cancer, the method comprising removing immune effector cells from a subject diagnosed with a MAGE-A4-expressing cancer, genetically modifying the immune effector cells with a vector comprising a nucleic acid encoding a chimeric antigen receptor of the present disclosure, thereby generating a population of modified immune effector cells, and administering the modified population of immune effector cells to the same subject. In one embodiment, the immune effector cells comprise T cells.
[0125] The method for applying the cell composition described herein includes any effective method for reintroducing the genetically modified immune effector cells of the CAR disclosed in the subject directly expressing the re-introduction or the genetically modified progenitor cells of the immune effector cells, and the immune effector cells are differentiated into mature immune effector cells expressing CAR when introduced into the subject. A method includes ex vivo transduction of peripheral blood T cells with a nucleic acid construct according to the present disclosure, and the transduced cells are returned to the subject.
[0126] Binding properties of chimeric antigen receptors and corresponding antibodies
[0127] As used herein, the term "binds" is in the context of a chimeric antigen receptor or corresponding antibody binding to, for example, a predetermined antigen, such as a cell surface protein or fragment thereof (or an antigen bound to a cell surface protein such as an HLA molecule). Binding generally refers to an interaction or association between at least two entities or molecular structures, such as an antigen binding domain:antigen interaction.
[0128] For example, when measured by, for example, surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using an antigen as a ligand and an antibody or chimeric antigen receptor as an analyte (or anti-ligand), binding affinity is typically about 10 -7 M or lower K D Value, such as about 10 -8 M or lower, such as about 10 -9 Or lower. Cell-based binding strategies such as fluorescence activated cell sorting (FACS) binding assays are also routinely used, and FACS data have a strong correlation with other methods, such as radioligand competitive binding and SPR (Benedict, CA, "Journal of Immunology (J Immunol Methods)" 1997, 201 (2): 223-31; Geuijen, CA et al. "Journal of Immunology" 2005, 302 (1-2): 68-77).
[0129] Thus, the chimeric antigen receptors or corresponding antibodies of the present disclosure bind to a predetermined antigen or cell surface molecule (receptor) with an affinity corresponding to K D The affinity of the chimeric antigen receptor or corresponding antibody of the present disclosure can bind to the MAGE-A4 antigen presented by HLA, such as the MAGE-A4 antigen presented by HLA-A2. According to the present disclosure, the chimeric antigen receptor or corresponding antibody of the present disclosure can bind to the MAGE-A4 antigen presented by HLA, such as the MAGE-A4 antigen presented by HLA-A2, with a K value that is equal to or less than ten times that of the non-specific antigen. D The affinity of the chimeric antigen receptor or corresponding antibody with a value below 0.05 can be considered as undetectable binding.
[0130] The term "K D "(M)" refers to the dissociation equilibrium constant of a specific antigen binding domain:antigen interaction or the dissociation equilibrium constant of the corresponding antibody to antigen. K D There is an inverse relationship between K and binding affinity, so K D The smaller the value, the higher the affinity, ie the stronger it is. Therefore, the term "higher affinity" or "stronger affinity" relates to a higher ability to form an interaction and therefore to a smaller K Dvalue, and conversely, the term "lower affinity" or "weaker affinity" relates to a lower ability to form an interaction, and thus K D In some cases, a particular molecule (e.g., a chimeric antigen receptor or a corresponding antibody) has a higher binding affinity (or K) for a partner molecule (e.g., antigen X) with which it interacts than the binding affinity of the molecule (e.g., a chimeric antigen receptor or a corresponding antibody) for another interacting partner molecule (e.g., antigen Y). D ) can be expressed as D value (lower or weaker affinity) divided by the smaller K D (higher or stronger affinity), for example, a binding ratio determined by a 5-fold or 10-fold greater binding affinity, as appropriate.
[0131] The term “k d "(Sec-1 or 1 / Sec) refers to the dissociation rate constant of a specific antigen binding domain:antigen interaction or chimeric antigen receptor or corresponding antibody. This value is also called k off value.
[0132] The term “k d "(M-1×sec-1 or 1 / M) refers to the association rate constant of a specific antigen binding domain:antigen interaction or chimeric antigen receptor or corresponding antibody.
[0133] The term "K A ” (M-1 or 1 / M) refers to the association equilibrium constant of a specific antigen binding domain:antigen interaction or chimeric antigen receptor or corresponding antibody. By a Divide by k d The association equilibrium constant was obtained.
[0134] The term "EC50" or "EC 50 ” refers to the half maximal effective concentration, which comprises the concentration of the chimeric antigen receptor that induces a response intermediate between the baseline and the maximum after a specified exposure time. EC 50 Substantially refers to the concentration of the chimeric antigen receptor at which 50% of its maximal effect is observed. In certain embodiments, EC 50 The value is equal to the concentration of the chimeric antigen receptor or corresponding antibody of the present disclosure that binds to cells expressing an antigen (e.g., a tumor-associated antigen such as MAGE-A4) at half maximal binding, as determined by, for example, a FACS binding assay. Thus, decreased or weaker binding is observed, with an increased EC 50 Or half of the maximum effective concentration.
[0135] In one embodiment, decreased binding can be defined as an increased EC 50 The chimeric antigen receptor or corresponding antibody concentration that is able to bind to half of the target cells maximally.
[0136] Sequence variants of chimeric antigen receptors
[0137] As compared to the corresponding germline sequence derived from the separate antigen binding domain of the corresponding antibody, the chimeric antigen receptor or the present disclosure may include one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains. Such mutations can be easily determined by comparing the amino acid sequences disclosed herein with germline sequences that can be obtained from, for example, public antibody sequence databases. The chimeric antigen receptor of the present disclosure may include an antigen binding domain derived from any of the exemplary CDR or variable region amino acid sequences disclosed herein, wherein one or more amino acids in one or more frameworks and / or CDR regions are mutated to the corresponding residues of the germline sequence of the derived corresponding antibody or mutated to the corresponding residues of another human germline sequence or mutated to the conservative amino acid substitutions of the corresponding germline residues (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, a person of ordinary skill in the art can easily produce many antibodies including one or more individual germline mutations or combinations thereof. In certain embodiments, V H Domain and / or V L All mutations of framework and / or CDR residues in domain are back to the residues found in the original germline sequence of the initial derived antigen-binding domains.In other embodiments, only some residues are mutated back to the original germline sequence, for example, only in the first 8 amino acids of FR1 or in the last 8 amino acids of FR4, the residue after the mutation found, or only in CDR1, CDR2 or CDR3, the residue after the mutation found.In other embodiments, one or more mutations of one or more CDR residues in framework and / or one or more CDR residues are one or more corresponding residues of different germline sequences (that is, germline sequences different from the germline sequence of the initial derived antigen-binding domains).In addition, antigen-binding domains of the present invention can contain any combination of two or more germline mutations in framework and / or CDR districts, for example, wherein some individual residues are mutated to the corresponding residues of specific germline sequences, and some other residues different from the original germline sequence can maintain or mutate to the corresponding residues of different germline sequences.
[0138] Biological properties of chimeric antigen receptors and corresponding antibodies
[0139] The present disclosure provides methods for obtaining a novel molecule having a high affinity (e.g., nanomolar or subnanomolar K D (value) Chimeric antigen receptor of the antigen binding domain of an antibody that binds to human MAGE-A4.
[0140] According to certain embodiments, the present disclosure provides chimeric antigen receptors having antigen binding domains derived from corresponding antibodies that bind with a K of less than about 5 nM. D Binding to human MAGE-A4 (e.g., at 25°C) as measured by surface plasmon resonance. In certain embodiments, the corresponding antibody has a K of less than about 20 nM, less than about 10 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 800 pM, less than about 700 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 50 pM, or less than about 25 pM. D Binding to MAGE-A4 as measured by surface plasmon resonance.
[0141] The present disclosure also provides chimeric antigen receptors having an antigen binding domain derived from a corresponding antibody that binds to MAGE-A4 with a dissociation half-life (t1 / 2) of greater than about 10 minutes or greater than about 125 minutes, as measured by surface plasmon resonance at 25° C. In certain embodiments, the corresponding antibody binds to MAGE-A4 with a t1 / 2 of greater than about 3 minutes, greater than about 4 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 100 minutes, greater than about 110 minutes, or greater than about 120 minutes, as measured by surface plasmon resonance at 25° C.
[0142] The present disclosure also provides chimeric antigen receptors having an antigen binding domain derived from a corresponding antibody that specifically binds to a human cell line expressing endogenous MAGE-A4 as determined by a FACS binding assay.
[0143] The present disclosure also provides engineered cells expressing a MAGE-A4-specific chimeric antigen receptor that (i) is activated by MAGE-A4-expressing cells and / or (ii) exhibits inhibition of tumor growth in immunocompromised mice bearing human multiple myeloma or melanoma xenografts.
[0144] Preparation of antigen binding domain
[0145] The antigen binding domain of the chimeric antigen receptor of the present invention is specific for a specific antigen (e.g., MAGE-A4) and can be prepared by any antibody generation technology known in the art. In certain embodiments, one or more of the individual components of the corresponding antibodies of the present invention (e.g., heavy chains and light chains) are derived from chimeric antibodies, humanized antibodies, or fully human antibodies. Methods for preparing such antibodies are well known in the art. For example, VELOCIMMUNE can be used TM One or more of the heavy and / or light chains are prepared using VELOCIMMUNE TM Technology (or any other human antibody production technology), high affinity chimeric antibodies are initially isolated to a specific antigen (e.g., MAGE-A4) with human variable regions and mouse constant regions. The antibodies are characterized and selected for desired properties, including affinity, selectivity, epitope, etc. As discussed herein, these human variable regions (or CDRs) can then be incorporated into the antigen binding domain of a chimeric antigen receptor.
[0146] Polynucleotides and vectors
[0147] The present disclosure also provides polynucleotides and vectors encoding the chimeric antigen receptors discussed herein.
[0148] In various embodiments, the polynucleotide may include an expression cassette or an expression vector (e.g., a plasmid for introduction into a bacterial host cell or a viral vector such as a baculovirus vector for transfection of an insect host cell or a plasmid or viral vector such as a lentivirus for transfection of a mammalian host cell).
[0149] In various embodiments, the polynucleotide and / or vector comprises a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 21 or a nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO: 22. In various embodiments, the polynucleotide and / or vector comprises a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 38 or a nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO: 39. In various embodiments, the polynucleotide and / or vector comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, or SEQ ID NO: 30.
[0150] Methods for engineering immune cells expressing chimeric antigen receptors
[0151] The present disclosure provides a method for preparing immune cells for immunotherapy, the method comprising introducing a polynucleotide or vector encoding one of the MAGE-A4-specific chimeric antigen receptors described herein into such immune cells ex vivo.
[0152] The present disclosure provides immune cells comprising a polynucleotide or lentiviral vector encoding one of the MAGE-A4-specific chimeric antigen receptors discussed herein. In some embodiments, these immune cells are used for immunotherapy (eg, treating cancer).
[0153] The present disclosure provides a method for genetically modifying immune cells to make them more suitable for allogeneic transplantation. According to a first aspect, immune cells can be made allogeneic, for example, by inactivating at least one gene expressing one or more components of a T cell receptor (TCR) as described in WO 2013 / 176915, which can be combined with the inactivation of genes encoding or regulating HLA or β2m protein expression. Therefore, the risk of graft-versus-host syndrome and graft rejection is significantly reduced. According to another aspect of the present disclosure, immune cells can be further manipulated to make immune cells more active or limit exhaustion by inactivating genes encoding proteins acting as "immune checkpoints", which act as regulators of T cell activation such as PD1 or CTLA-4.
[0154] Engineered immune cells
[0155] The present disclosure also provides immune cells (e.g., engineered immune cells) comprising chimeric antigen receptors as described herein. In some cases, the immune cell is an immune effector cell. In some cases, the immune cell is a T cell. In some cases, the immune cell is a T lymphocyte selected from inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes, or helper T lymphocytes. In some cases, the immune cell is a CD8+ cytotoxic T lymphocyte.
[0156] In some embodiments, the engineered immune cell is a human T cell comprising a chimeric antigen receptor, which comprises, from N-terminus to C-terminus: (a) an extracellular ligand binding domain comprising an anti-MAGE-A4 single-chain variable fragment (scFv) domain, wherein the anti-MAGE-A4 scFv domain comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR); (b) a hinge; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain.
[0157] In some embodiments, the scFv domain of the engineered human T cell comprises a HCVR / LCVR amino acid sequence pair comprising the amino acid sequence of SEQ ID NO: 2 / 10. In some embodiments, the scFv domain of the engineered human T cell comprises a HCVR / LCVR amino acid sequence pair comprising the amino acid sequence of SEQ ID NO: 2 / 37. In some cases, the hinge comprises the amino acid sequence of SEQ ID NO: 27. In some cases, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 28. In some cases, the costimulatory domain is a 4-1BB costimulatory domain. In some cases, the 4-1BB costimulatory domain comprises the amino acid sequence of SEQ ID NO: 29. In some cases, the signaling domain is a CD3 zeta signaling domain. In some cases, the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 30.
[0158] In various embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 22. In various embodiments, the engineered human T cells comprise a chimeric antigen receptor comprising the amino acid sequence of SEQ ID NO: 39.
[0159] Bioequivalent
[0160] The present disclosure provides chimeric antigen receptors and engineered cells expressing chimeric antigen receptors, which have amino acid sequences that differ from the amino acid sequences of the exemplary molecules disclosed herein but retain the ability to bind to MAGE-A4, activate immune cells expressing chimeric antigen receptors in the presence of MAGE-A4 expressing cells, or inhibit the growth or proliferation of MAGE-A4 expressing tumor cells. Such variant molecules may include one or more additions, deletions or substitutions of amino acids when compared to the parent sequence, but exhibit biological activity that is substantially equivalent to the biological activity of the described bispecific antigen binding molecules.
[0161] In one embodiment, two engineered immune cells expressing a chimeric antigen receptor of the present disclosure are bioequivalent if there are no clinically meaningful differences in safety, purity, and potency between the two engineered immune cells.
[0162] In one embodiment, two engineered immune cells are bioequivalent if a patient can switch between the reference product and the biological product one or more times without an expected increased risk of adverse effects, including a clinically significant change in immunogenicity, or a decrease in effectiveness, as compared to continued therapy without such switching.
[0163] In one implementation, two engineered immune cells are bioequivalent if both engineered immune cells act by a common mechanism or mechanisms of action for the disorder or condition of use (provided such mechanisms are known).
[0164] Bioequivalence can be demonstrated by in vivo and in vitro methods. Bioequivalence metrics include, for example: (a) in vivo testing in humans or other mammals, where the concentration of engineered cells is measured over time in blood, plasma, serum or other biological fluids; (b) in vitro tests that are correlated with and reasonably predictive of human in vivo bioavailability data; (c) in vivo testing in humans or other mammals, where appropriate acute pharmacological effects of the engineered cells (or their targets) are measured over time; and (d) in well-controlled clinical trials that establish the safety, efficacy or bioavailability or bioequivalence of the engineered cells.
[0165] Bioequivalent variants of the exemplary engineered cells described herein can be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences that are not essential for biological activity.
[0166] Species selectivity and cross-species reactivity
[0167] According to certain embodiments of the present disclosure, antigen binding domains are provided that bind to human MAGE-A4 but not to MAGE-A4 from other species. The present disclosure also provides antigen binding domains that bind to human MAGE-A4 and to MAGE-A4 from one or more non-human species. In some embodiments, the antigen binding domains of the present disclosure bind to MAGE-A4 286-294 or 230-239. In some embodiments, the MAGE-A4 (e.g., MAGE-A4 286-294 or 230-239) bound by the antigen binding domain is presented on the cell surface by HLA, such as HLA-A2.
[0168] According to certain exemplary embodiments of the present disclosure, an antigen binding domain is provided that binds to human MAGE-A4 and may or may not bind to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cattle, horse, camel, cynomolgus monkey, marmoset, rhesus monkey, or chimpanzee MAGE-A4, as appropriate. In addition, binding to MAGE-A4 may be in the context of MHC-presented MAGE-A4, such as HLA-presented MAGE-A4. An exemplary HLA-presented MAGE-A4 is HLA-A2-binding human MAGE-A4.
[0169] Activation and expansion of engineered immune cells
[0170] Whether before or after genetic modification of engineered cells (e.g., T cells), even if the genetically modified immune cells of the present disclosure are activated and proliferated independently of the antigen binding mechanism, the immune cells of the present disclosure, particularly T cells, can be further activated and expanded using, for example, methods as described in the following: U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,85 T cells can be expanded in vitro or in vivo.
[0171] Typically, the T cells of the present disclosure are expanded by contacting with agents that stimulate the CD3 TCR complex and co-stimulatory molecules on the surface of the T cells to generate activation signals for the T cells. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristic acid 13-acetate (PMA), or mitogenic lectins such as phytohemagglutinin (PHA) can be used to generate activation signals for the T cells.
[0172] As a non-limiting example, T cell groups can be stimulated in vitro, such as by contacting with anti-CD3 antibodies or their antigen binding fragments or anti-CD2 antibodies fixed on the surface or by contacting with protein kinase C activators (e.g., bryostatin) and calcium ion carriers. For the costimulation of auxiliary molecules on the surface of T cells, a ligand in conjunction with auxiliary molecules is used. For example, under conditions suitable for stimulating T cell proliferation, T cell groups can be contacted with anti-CD3 antibodies and anti-CD28 antibodies. Conditions suitable for T cell culture include appropriate culture medium (e.g., minimal essential medium or RPMI culture medium 1640 or X-vivo 5 (Lonza (Lonza))), the culture medium may contain factors necessary for proliferation and vigor, the factors include serum (e.g., fetal bovine or human serum) for cell growth known to those skilled in the art, interleukin-2 (IL-2), insulin, IFN-g, IL-4, IL-7, GM-CSF, IL-10, IL-2, IL-15, TGFp and TNF-α or any other additives. Other additives for cell growth include, but are not limited to, surfactants, plasma acid salts, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. The culture medium may include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1 and X-Vivo 20, Optimizer, which are supplemented with amino acids, sodium pyruvate, and vitamins, which are serum-free or supplemented with an appropriate amount of serum (or plasma) or a set of defined hormones and / or one or more cytokines sufficient to grow and expand T cells. Antibiotics (e.g., penicillin and streptomycin) are included only during experimental culture, and are not included when culturing cells to be injected into a subject. Target cells are maintained under conditions required to support growth, such as appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% O2). T cells exposed to different stimulation times may exhibit different characteristics.
[0173] In some embodiments, the cells can be expanded by co-culturing with tissues or cells. The cells can also be expanded in vivo, for example in the blood of a subject after the cells are administered to the subject.
[0174] Therapeutic applications
[0175] The present disclosure provides compositions comprising engineered cells (e.g., T cells) expressing chimeric antigen receptors of the present disclosure and pharmaceutically acceptable vehicles. In some cases, engineered cells form medicines, particularly for immunotherapy. In some cases, engineered cells are used to treat cancer (e.g., multiple myeloma or melanoma). In some cases, engineered cells are used to manufacture medicines for immunotherapy and / or treatment of cancer (e.g., MAGE-A4 expression cancer).
[0176] The present disclosure provides methods comprising administering to a subject in need thereof a therapeutic composition comprising an engineered cell (e.g., T cell) expressing a chimeric antigen receptor as discussed herein. The therapeutic composition may include a cell expressing any chimeric antigen receptor as disclosed herein and a pharmaceutically acceptable carrier, diluent, or vehicle. As used herein, the expression "subject in need thereof" means a human or non-human animal that exhibits one or more symptoms or signs of cancer (e.g., a subject with a MAGE-A4-expressing tumor or with any of the cancers mentioned herein) or that otherwise benefits from inhibition or reduction of MAGE-A4 activity or depletion of MAGE-A4+ cells.
[0177] The engineered cells of the present disclosure can be used, in particular, to treat any disease or condition in which stimulation, activation and / or targeting of an immune response would be beneficial. Specifically, the engineered cells of the present disclosure can be used to treat, prevent and / or ameliorate any disease or condition associated with or mediated by MAGE-A4 expression or activity or MAGE-A4+ cell proliferation. Cells expressing MAGE-A4 that can be inhibited or killed using the engineered cells of the present disclosure include, for example, multiple myeloma cells, melanoma cells, or other solid tumor cells.
[0178] The engineered cells of the present disclosure can be used to treat diseases or conditions associated with MAGE-A4 expression, including, for example, cancers, including but not limited to multiple myeloma, synovial sarcoma, esophageal cancer, head and neck cancer, lung cancer, bladder cancer, ovarian cancer, uterine cancer, gastric cancer, cervical cancer, breast cancer, and melanoma. The engineered cells of the present disclosure can generally be used to treat tumors expressing MAGE-A4. According to other related embodiments of the present disclosure, there is provided a method comprising administering an engineered cell as disclosed herein to a patient suffering from a tumor expressing MAGE-A4, the tumor comprising a tumor from the cancers listed above. Analysis / diagnostic methods known in the art, such as tumor scanning, can be used to determine whether a patient suffers from such a tumor, disease, or condition.
[0179] The present disclosure also provides methods for treating residual cancer in a subject.As used herein, the term "residual cancer" means the presence or persistence of one or more cancer cells in a subject after treatment with an anti-cancer therapy.
[0180] According to certain aspects, the disclosure provides methods for treating a disease or condition associated with MAGE-A4 expression (e.g., cancer), the method comprising administering to a subject an engineered cell population described elsewhere herein after determining that the subject suffers from the disease or condition. For example, the disclosure provides methods for treating a disease or condition, the method comprising administering to a patient an engineered immune cell 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks or 4 weeks, 2 months, 4 months, 6 months, 8 months, 1 year or more after the subject has received other immunotherapy or chemotherapy.
[0181] Treatments discussed herein can be ameliorative, curative or preventive. Treatment can be part of an autologous immunotherapy or part of an allogeneic immunotherapy. Autologous means that the cells, cell lines or cell populations used to treat a patient are derived from the patient or a human leukocyte antigen (HLA) compatible donor. Allogeneic means that the cells, cell lines or cell populations used to treat a patient are not derived from the patient but from a donor.
[0182] Cells that can be used with the disclosed methods are described herein. Therapeutics can be used to treat patients diagnosed with a pre-malignant or malignant cancer condition characterized by MAGE-A4 expressing cells, particularly an excess of MAGE-A4 expressing cells. Such conditions can be found in cancer.
[0183] Cancer types to be treated with the engineered cells of the present disclosure include, but are not limited to, multiple myeloma, synovial sarcoma, esophageal cancer, head and neck cancer, lung cancer, bladder cancer, ovarian cancer, uterine cancer, gastric cancer, cervical cancer, breast cancer, and melanoma.
[0184] The compositions and methods of the present disclosure can be used to treat subjects that have been characterized as having cells or tissues expressing MAGE-A4 or suspected of having cells or tissues expressing MAGE-A4. For example, subjects that benefit from treatment according to the present disclosure include subjects with multiple myeloma, synovial sarcoma, esophageal cancer, head and neck cancer, lung cancer, bladder cancer, ovarian cancer, uterine cancer, gastric cancer, cervical cancer, breast cancer, or melanoma.
[0185] The administration of cells or cell groups according to the present disclosure can be carried out in any convenient manner, including aerosol inhalation, injection, ingestion, infusion, implantation or transplantation. The compositions described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intramedullaryly, intramuscularly, intravenously or intralymphatically, or intraperitoneally. In one embodiment, the cell composition of the present disclosure is preferably administered by intravenous injection.
[0186] Administration of the cells or cell populations may consist of administering 10 4 -10 9 cells per kg body weight, preferably 105 Up to 10 6 Cells per kg body weight, including all integer values of the number of cells within those ranges. Cells or cell groups can be administered in one or more doses. In certain embodiments, an effective amount of cells is administered as a single dose. In certain embodiments, an effective amount of cells is administered as more than one dose over a period of time. The administration time is within the discretion of the attending physician and depends on the clinical condition of the patient. Cells or cell groups can be obtained from any source, such as a blood bank or a donor. Although individual needs vary, the determination of the scope of the effective amount of a given cell type for the treatment of a particular disease or condition is within the technical scope of the art. An effective amount means the amount providing a therapeutic or preventive benefit. The dosage administered will depend on the age, health and weight of the recipient, the type of concurrent treatment (if any), the frequency of treatment, and the nature of the desired effect.
[0187] In one embodiment, an effective amount of cells or a composition comprising those cells is administered parenterally. Such administration may be intravenous administration. In some cases, administration may be performed directly by injection into a tumor.
[0188] In certain embodiments of the present disclosure, the cells are administered to a patient in combination with (e.g., before, simultaneously with, or after) any number of relevant therapeutic modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (also known as ARA-C), or natalizumab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the present disclosure can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporin, azathioprine, methotrexate, mycophenolate and FK506, antibodies or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytotoxins, fludaribine, cyclosporine, FK506, rapamycin, mycoplienolic acid, steroids, FR901228, cytokines and radiation.
[0189] In other embodiments, the cell compositions of the present invention are administered to patients in combination (e.g., before, at the same time, or after) with bone marrow transplantation, T cell ablation therapy using chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cell compositions of the present invention are administered after B cell ablation therapy such as agents that react with CD20, such as Rituxan. For example, in one embodiment, the subject may undergo standard treatment, wherein high-dose chemotherapy is followed by peripheral blood stem cell transplantation. In certain embodiments, after transplantation, the subject receives an infusion of amplified immune cells of the present invention. In other embodiments, amplified cells are administered before or after surgery. In certain embodiments, before administering the amplified immune cells of the present invention, any means (e.g., surgery, chemotherapy, or radiotherapy) can be used to reduce tumor burden. In one embodiment, reducing tumor burden before administering the engineered cells of the present invention can reduce the possibility of cytokine release syndrome or cytokine storm (a side effect that may be associated with CAR T cell therapy) or prevent it.
[0190] Combination therapy
[0191] The present disclosure provides a method comprising administering an engineered cell or cell group in combination with one or more additional therapeutic agents, the cell group comprising any chimeric antigen receptor described herein. Exemplary additional therapeutic agents that can be combined with the cells or cell groups of the present disclosure or can be administered in combination with the cells or cell groups of the present disclosure include, for example, anti-tumor agents (e.g., chemotherapeutic agents, including melphalan, vincristine (vincristine) (Oncovin), cyclophosphamide (Cytoxan), etoposide (etoposide) (VP-16), doxorubicin (doxorubicin) (Adriamycin), liposomal doxorubicin (Doxil), bendamustine (bendamustine) (Treanda) or any other chemotherapeutic agent known to be effective for treating plasma cell tumors in subjects). In some embodiments, the second therapeutic agent includes a steroid. In some embodiments, the second therapeutic agent comprises a targeted therapy comprising thalidomide, lenalidomide, and bortezomib, which are approved therapies for treating newly diagnosed patients. For example, lenalidomide, pomalidomide, bortezomib, carfilzomib, panobinostat, ixazomib, elotuzumab, and daratumumab are examples of second therapeutic agents for effective treatment of relapsed myeloma. In certain embodiments, the second therapeutic agent is a regimen comprising radiation therapy or stem cell transplantation. In certain embodiments, the second therapeutic agent may be an immunomodulator. In certain embodiments, the second therapeutic agent may be a proteasome inhibitor, comprising bortezomib. Carfilzomib Ishazomi In certain embodiments, the second therapeutic agent may be a histone deacetylase inhibitor, such as panobinostat. In certain embodiments, the second therapeutic agent can be a monoclonal antibody, an antibody drug conjugate, a bispecific antibody conjugated to an anti-tumor agent, a checkpoint inhibitor, or a combination thereof. Other agents that can be beneficially combined with the antigen binding molecules of the present disclosure include cytokine inhibitors, which include small molecule cytokine inhibitors and antibodies that bind to cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, IL-18, or their respective receptors. The pharmaceutical compositions of the present disclosure (e.g., pharmaceutical compositions comprising engineered cells or cell populations as disclosed herein) can also be administered as part of a treatment regimen comprising one or more therapeutic combinations selected from the following: a monoclonal antibody different from the monoclonal antibodies described herein, which can interact with a different antigen on the surface of a plasma cell; a bispecific antibody, one arm of which binds to an antigen on the surface of a tumor cell and the other arm binds to an antigen on a T cell; an antibody drug conjugate; a bispecific antibody conjugated to an anti-tumor agent; a checkpoint inhibitor, such as a checkpoint inhibitor targeting PD-1 or CTLA-4; or a combination thereof. In certain embodiments, the checkpoint inhibitor can be selected from a PD-1 inhibitor, such as pembrolizumab Nivolumab or cemiplimab In certain embodiments, the checkpoint inhibitor may be selected from a PD-L1 inhibitor, such as atezolizumab Avelumab or Durvalumab In certain embodiments, the checkpoint inhibitor may be selected from CTLA-4 inhibitors, such as ipilimumab
[0192] The present disclosure also includes therapeutic combinations, which include any of the engineered cells or cell populations mentioned herein and an inhibitor of one or more of VEGF, Ang2, DLL4, EGFR, ErbB2, ErbB3, ErbB4, EGFRvIII, cMet, IGF1R, B-raf, PDGFR-α, PDGFR-β, FOLH1 (PSMA), PRLR, STEAP1, STEAP2, TMPRSS2, MSLN, CA9, uroplakin, or any of the above cytokines, wherein the inhibitor is an aptamer, an antisense molecule, a ribozyme, siRNA, a peptibody, a nanobody, or an antibody fragment (e.g., a Fab fragment; a F(ab')2 fragment; a Fd fragment; a Fv fragment; a scFv; a dAb fragment; or other engineered molecules such as double antibodies, three antibodies, four antibodies, micro antibodies, and minimal recognition units). In some embodiments, the engineered cells or cell populations of the present disclosure can also be administered as part of a treatment regimen that also includes radiation therapy and / or conventional chemotherapy.
[0193] One or more additional therapeutically active ingredients may be administered prior to, concurrently with, or after administration of the engineered cells of the disclosure; (for purposes of the present disclosure, such administration regimens are considered administration of the engineered cells "in combination" with the additional therapeutically active components).
[0194] The present disclosure provides pharmaceutical compositions in which the engineered cells or cell populations of the present disclosure are co-formulated with one or more of the additional therapeutically active components as described elsewhere herein.
[0195] Administration regimen
[0196] According to certain embodiments of the present disclosure, multiple doses of engineered cells can be administered to a subject within a limited time course. Methods according to this aspect include sequentially administering multiple doses of cells to a subject. As used herein, "sequential administration" means that each dose is administered to a subject at different time points, for example, on different dates separated by a predetermined interval (e.g., hours, days, weeks or months). The present disclosure provides methods including sequentially administering a single initial dose to a patient, followed by one or more second doses, and optionally followed by one or more third doses.
[0197] The terms "initial dose", "secondary dose" and "tertiary dose" refer to the temporal order of administration of the engineered cells of the present disclosure. Therefore, the "initial dose" is the dose (also referred to as the "baseline dose") administered at the beginning of the treatment regimen; the "secondary dose" is the dose administered after the initial dose; and the "tertiary dose" is the dose administered after the second dose. The initial dose, the second dose, and the third dose may all contain the same amount of engineered cells, but may generally differ from each other in terms of the frequency of administration. However, in certain embodiments, during the course of treatment, the amount of engineered cells contained in the initial dose, the second dose, and / or the third dose differs from each other (e.g., appropriately adjusted up or down). In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered as "loading doses" at the beginning of the treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered on a less frequent basis.
[0198] In an exemplary embodiment of the present disclosure, each second dose and / or third dose is administered 1 to 26 (e.g., 1, 1 1 / 2,2,2 1 / 2,3,3 1 / 2,4,4 1 / 2,5,5 1 / 2,6,6 1 / 2,7,7 1 / 2,8,8 1 / 2,9,9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 25 1 / 2, 26, 26 1 / 2 or more) weeks. As used herein, the phrase "immediately following the previous dose" means a dose administered to a patient prior to the administration of the next dose in the sequence without an intervening dose in the order of multiple administrations.
[0199] The method according to this aspect of the present disclosure may include administering any number of second and / or third doses to the patient. For example, in certain embodiments, only a single second dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) second doses are administered to the patient. Similarly, in certain embodiments, only a single third dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) third doses are administered to the patient.
[0200] In embodiments involving multiple second doses, each second dose can be administered at the same frequency as other second doses. For example, each second dose can be administered to the patient 1 to 2 weeks after the previous dose. Similarly, in embodiments involving multiple third doses, each third dose can be administered at the same frequency as other third doses. For example, each third dose can be administered to the patient 2 to 4 weeks after the previous dose. Alternatively, the frequency of administering the second dose and / or the third dose to the patient can vary during the course of the treatment regimen. The frequency of administration can also be adjusted during the physician's treatment process according to the needs of individual patients after clinical examination.
[0201] Examples
[0202] The following examples are presented to provide a complete disclosure and description of how to prepare and use the disclosed methods and compositions to those of ordinary skill in the art, and are not intended to limit the scope of what the inventors consider to be their invention. Efforts have been made to ensure accuracy with respect to the numerals used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is degrees Celsius, and pressure is or is close to atmospheric pressure.
[0203] Example 1: Generation of anti-MAGE-A4 antibodies
[0204] Anti-MAGE-A4 antibodies are obtained by immunizing genetically modified mice (e.g., mice engineered to include DNA encoding human immunoglobulin heavy chain and kappa light chain variable regions) with a human MAGE-A4 antigen (e.g., hMAGE-A4 230-239 for mAb31345 or hMAGE-A4 286-294 for mAb33229) and HLA-A2.
[0205] After immunization, spleen cells are harvested from each mouse and either (1) fused with mouse myeloma cells to maintain their viability and form hybridoma cells and screened for MAGE-A4 specificity or (2) B cells are sorted using human MAGE-A4 fragments as sorting agents to bind and identify reactive antibodies (antigen-positive B cells) (as described in U.S. Patent Publication No. 2007 / 0280945A1).
[0206] Initially, chimeric antibodies against MAGE-A4 with human variable regions and mouse constant regions are isolated. Antibodies are characterized and selected for desired characteristics, including affinity, selectivity, etc. If desired, the mouse constant region is replaced with a desired human constant region (e.g., a wild-type or modified IgG1 or IgG4 constant region) to generate fully human anti-MAGE-A4 antibodies. Although the constant region selected can vary depending on the specific application, high affinity antigen binding and target specificity properties are present in the variable region.
[0207] Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences of Anti-MAGE-A4 Antibodies: Table 1 shows the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-MAGE-A4 antibodies of the present disclosure. The mAb31345 and mAb31345* sequences of Table 1 are identical except for one additional C-terminal amino acid in the "called" LCVR sequence of mAb31345* (i.e., the full-length antibodies are identical, but when annotating the LCVR region, one additional amino acid was assigned to the LCVR of mAb31345*). The corresponding nucleic acid sequence identifiers are listed in Table 2. A summary of all sequences contained herein is provided in Table 56.
[0208] Table 1: Amino Acid Sequence Identifiers
[0209]
[0210] Table 2: Nucleotide sequence identifiers
[0211]
[0212] Example 2: Generation of MAGE-A4-specific chimeric antigen receptors
[0213] The anti-MAGE-A4 31345 and 33229 antibodies of Table 1 were reformatted into VL-VH single chain variable fragments (ScFv) and placed into chimeric antigen receptor (CAR) constructs using CD8α hinge and transmembrane domains, 4-1BB co-stimulatory domains, and CD3ζ stimulatory domains or CD28 hinge, transmembrane and signaling domains using HCVR and LCVR nucleotide sequences of anti-MAGE-A4 antibodies corresponding to SEQ ID NOs: 1 and 36, respectively. The corresponding full-length nucleic acid and polypeptide heavy chain sequences of the 31345 anti-MAGE-A4 antibodies correspond to SEQ ID NOs: 17 and 18, respectively. The corresponding full-length nucleic acid and polypeptide light chain sequences of the 31345 anti-MAGE-A4 antibodies correspond to SEQ ID NOs: 19 and 20, respectively. Full-length nucleic acid and polypeptide 31345 HLA-A2 / MAGE-A4 286-294The targeting CAR sequences correspond to SEQ ID NOs: 38 and 39, respectively. As a non-binding control, a similar CAR was designed using the nucleotide sequence of an unrelated scFv (CAR construct of SEQ ID NO: 34; the polypeptide sequence of the control CAR corresponds to SEQ ID NO: 35). The MAGE-A4-specific CAR was cloned into a lentiviral expression vector (Lenti-X TM The lentiviral particles were generated by the Lenti-X packaging single-shot (VSV-G) system (Clontech catalog number 631276). The lentiviral particles were then expressed using the manufacturer's protocol. Pre-coated dishes (Clontech catalog number T110a) were transduced with CAR constructs to engineer Jurkat cells expressing NFKB-luciferase reporter genes (Jurkat / NKFBLuc cl 1C11). After selection for at least 2 weeks in 500 μg / ml G418 (Gibco, catalog number 11811-098), the following CAR T cell lines were generated; Jurkat / NKFBLuc cl 1C11 / MAGE-A4 (286-294) 31345VL-VH CART. As a non-binding control, a similar CAR was designed using the nucleotide sequence of an unrelated scFv. The cell surface expression and functional activity of this CAR T cell line in response to MAGE-A4 expressing cells were evaluated.
[0214] Example 3: Cell surface expression of MAGE-A4 CAR constructs in Jurkat cells and activation of MAGE-A4 CAR T cells
[0215] The relative level of cell surface expression of MAGE-A4 CAR constructs in Jurkat / Jurkat / NKFBLuc cells was assessed by flow cytometry. For staining, cells were seeded in a staining buffer of PBS (Irving 9240) and 2% FBS (ATCC 30-2020) without calcium and magnesium at a density of 200,000 cells per well in a 96-well V bottom plate, and stained with 10 μg / ml of protein L (Genscript biotin protein L) at 4 ° C for 30 minutes. After incubation, the cells were washed once in staining buffer and stained with streptavidin Alexa-647 secondary antibody (Biolegend) at 0.5 μg / ml at 4 ° C for 30 minutes. The cells were then washed and fixed using a 50% solution of BD Cytofix (Becton Dickinson) diluted in staining buffer. Samples were run on an Intellicyt iQue flow cytometer and analyzed by FlowJo 10.2 to calculate median fluorescence intensity (MFI). The percentage of protein L positive cells (Table 3) was calculated by taking the percentage of protein L positive cells relative to the total number of cells.
[0216] The activity of CAR T cell lines was evaluated in CAR T / APC (antigen presenting cell) bioassays. For bioassays, 50,000 CAR T cells were added to Thermo-Nunc 96-well white plates (Thermo Fisher Scientific) in 50 μl of assay medium (RPMI medium with 10% FBS and 1% P / S / G), and then 3-fold serial dilutions of APC (500,000 cells to 685 cells) were added in 50 μl of assay medium. The following APCs were used: IM9 (which endogenously expresses MAGE-A4 286-294 peptide) and HEK293 (which is MAGE-A4 286-294 negative). The cell mixture was incubated in a humidified incubator at 37 ° C, 5% CO2 for 5 hours. NFKB-luciferase activity was measured using One-Glo and Perkin Elmer Envision microplate reader. Relative luciferase units (RLU) were generated on 8-point response curves using a four-parameter logistic equation and plotted in GraphPad Prism. The zero APC condition for each dose-response curve is also included in the analysis as a continuation of a three-fold serial dilution, and is expressed as the lowest dose. The maximum CAR T activity is determined by taking the ratio of the highest RLU to the lowest RLU on the curve, and is expressed as signal: noise (S:N) in Table 4. Tables 3 and 4 show the results of protein L staining and MAGE-A4 CAR T cell activation.
[0217] Table 3: Protein L staining of CAR in Jurkat / NFKBLuc cl 1C11 cells
[0218] Cell lines Protein L positive % Jurkat / NFKBLuc cl.1C11 3.9 Jurkat / NFKBLuc cl.1C11 / MAGE-A4(286-294)31345VL-VH CAR T-cell 49.9 Jurkat / NFKBLuc cl.1C11 / control VL-VH CAR T-cells 67.2
[0219] Table 3 shows the percentage of CAR-positive Jurkat / NFKBLuc cells measured by protein L staining. The MAGE-A4-specific CAR generated by mAb31345 was expressed in 49.9% of cells, while the non-targeting control CAR was expressed in 67.2% of cells, and CAR expression was found in only 3.9% of the negative control (Jurkat / NFKBLuc cl.1C11) cells.
[0220] Table 4: Activation of MAGE-A4 CAR T cells in CAR T cell / APC bioassay
[0221]
[0222] Table 4 shows that the HLA-A2:MAGE-A4(286-294)31345CAR T cell line was activated by IM9 cells with a signal-to-noise ratio of 35.0, while the HLA-A2:MAGE-A4(286-294)CAR T cell line was not activated by the HEK 293 negative control cell line.
[0223] Example 4: Generation of CAR T cells expressing MAGE-A4-specific CAR
[0224] The CAR of Example 2 (containing anti-MAGE-A4 VL-VH scFv, huCD8 transmembrane domain, 4-1BB co-stimulatory domain and CD3ζ signaling domain, and constructed using HCVR and LCVR nucleotide sequences corresponding to SEQ ID NOs: 1 and 36, respectively, of the anti-MAGE-A4 antibody) and the non-binding control CAR of Example 2 (CAR construct of SEQ ID NO: 34; the polypeptide sequence of the control CAR corresponds to SEQ ID NO: 35) were cloned into a pLVX lentiviral vector with an EF1a promoter and an IRES: eGFP sequence (for tracking CAR transduced cells), and VSV pseudotype lentivirus was produced. CD3+T cells were then isolated from human peripheral blood mononuclear cells (PBMCs), stimulated with CD3 / CD28 microbeads plus 100U / ml recombinant human IL-2, and transduced with lentivirus at MOI=5. The transduced cells were expanded with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2 for 19 days and then cryopreserved until use during in vivo experiments. These CAR T cell lines were used to evaluate in vitro cytotoxicity and efficacy in reducing tumor burden in vivo.
[0225] Example 5: MAGE-A4-specific CAR T cells mediate cytolysis of MAGE-A4-expressing cells
[0226] CD3+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs), stimulated with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2, and transduced with lentivirus at MOI = 5 as described above. Prior to setting up the cell lysis assay, the transduced cells were expanded for 19 days with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2.
[0227] To determine the cytolytic capacity of MAGE-A4-targeted chimeric antigen receptor (CAR) T cells, cytolytic assays were performed using expanded CART cells and various tumor target cell lines expressing different levels of MAGE-A4. On the 19th day of expansion, the expanded CAR T cells were co-cultured three times with calcein-labeled MAGE-A4+ or control target cell lines at different ratios. Calcein is a cell-permeable fluorescent dye with excitation and emission wavelengths of 495 and 515 nm, respectively. After 2.5 hours, the percentage of cytotoxicity was calculated based on the amount of calcein dye released by the target cells, which occurs when membrane integrity fails, such as ((calcein signal-calcein spontaneous release) / (calcein maximum release-calcein spontaneous release))*100. To determine the maximum calcein release, the target cells were treated with 1% Triton-X-114 detergent solution during the assay. To determine spontaneous calcein release, MAGE-A4+ target cells were labeled with calcein and then cultured in the absence of CAR T cells.
[0228] 2-hour Calcein cytotoxicity assay : At the time of harvesting, the expanded CAR T cells were washed and resuspended in Optimizer Cell Culture Medium. Each target cell line was harvested and cultured at 2×10 6 The target cells were resuspended at a density of 100 μg / mL and then calcein-AM dye was added at a concentration of 8 μM for 35 minutes at 37°C. After calcein labeling, the target cells were washed twice to remove additional calcein. Subsequently, T cells and target cells were co-cultured in 96-well round-bottom plates at various ratios and cultured at 37°C for 2.5 hours while the culture supernatant was harvested. For negative controls, target cells were co-cultured with T cells generated using a similar CAR designed to contain a CAR that does not recognize HLA-A2-binding MAGE-A4 286-294 Irrelevant scFv. This CARscFv control is an anti-HLA-A2 / HPV16E7 (11-19) scFv (in the VL-VH orientation). Lentivirus was used as a vector to introduce scFvs into cells. As a CAR negative control, non-transduced and expanded T cells from the same normal healthy donor were used. As a control for antigen-specific CAR T cell-mediated killing, the 293T human embryonic kidney cell line expressing the SV40 antigen was used because this cell line is negative for MAGE-A4 expression. To determine whether calcein is spontaneously released from the MAGE-A4+ target cell line, each cell line was cultured in the absence of CAR T cells. To determine the maximum possible release of calcein, supplementation with 1% Triton TMThe target cell lines were cultured and lysed in Optmizer medium without X-114 detergent. In the supernatant, the relative calcein level was measured using a Viktor X4 plate reader, and the cytotoxicity percentage was calculated as ((calcein signal-calcein spontaneous release) / (calcein maximum release-calcein spontaneous release))*100.
[0229] The cell lines used for this assay included the following: A375 human melanoma tumor cell line ( Cell Line Number: CRL-9068 TM ); A375 human melanoma tumor cell line (ATCC, cell line number: CRL-9068 TM ), which is engineered to overexpress MAGE-A4 286-294 HLA-A2 polypeptide; IM9 multiple myeloma cell line (DSMZ, catalog number: ACC569); IM9 multiple myeloma cell line (DSMZ, catalog number: ACC569 TM ), which is engineered to overexpress MAGE-A4 286-294 HLA-A2 polypeptide; 293T human embryonic kidney cell line expressing SV40 antigen ( Cell Line Number: CRL-3216 TM ) and CaSKI cervical epidermoid carcinoma ( CRL-1550 TM ), which is engineered to overexpress HPV16E7 11-19 Peptide of HLA-A2.
[0230] like Figure 2A and Figure 2B As shown in Tables 5, 6 and 7, the HLA-A2 / MAGE-A4 286-294 - Culture composed of targeted CAR+T cells: A375 cells induced by 31345scFv ( Figure 2A : hollow black circle, dotted line), overexpression of HLA-A2 / MAGE-A4 286-294 A375 cells ( Figure 2A : Solid black circles, solid lines, representing A375++), IM9 cells ( Figure 2B : hollow black circles, dotted lines) and overexpression of HLA-A2 / MAGE-A4 286-294 IM9 cells ( Figure 2B : Solid black circles, solid line, indicated as IM9++). Higher levels of cytotoxicity were observed against endogenous IM9 cells relative to A375 cells. 286-294Overexpression in A375 cells did not increase the level of cytotoxicity. Without wishing to be bound by theory, this result may be because IM9 cells express higher levels of MAGE-A4 antigen than A375 cells.
[0231] Table 5: HLA-A2 / MAGE-A4 286-294 -Directed CAR T cell lysis
[0232]
[0233] SD: Standard deviation
[0234] Table 6: HLA-A2 / MAGE-A4 286-294 - Directed CAR T cell lysis, plate 1
[0235]
[0236] SD: Standard deviation
[0237] Table 7: HLA-A2 / MAGE-A4 286-294 - Directed CAR T cell lysis, plate 2
[0238]
[0239] SD: Standard deviation
[0240] As shown in Tables 5, 6 and 7, untransduced and expanded (MOI 0) T cells and CAR T cells expressing CARs that are non-specific for MAGE-A4, when co-cultured with MAGE-A4+ target cells (A375, A375++, IM9, IM9++), failed to cause significant cytolysis of target cells relative to MAGE-A4+ tumor cells, even at the maximum ratio of 50 T cells to one target cell. These results indicate that only when the CAR construct contains a CAR that recognizes HLA-A2 / MAGE-A4 286-294 Cell lysis was only observed when 31345scFv was added. 286-294 Targeted CAR T cells demonstrated negligible cytotoxicity against 293T cells lacking MAGE-A4 expression, indicating that MAGE-A4 expression was required for the observed cytolysis.
[0241] Example 6: MAGE-A4-targeted CAR T cells reduce the growth of MAGE-A4-expressing tumors in vivo in a xenogeneic melanoma model
[0242] To determine HLA-A2 / MAGE-A4 286-294The in vivo efficacy of targeted chimeric antigen receptor (CAR) T cells was studied in xenografts in mice using A375 human melanoma tumor cells expressing MAGE-A4. scid Iq tm1Wjl / SzJ (NSG) mice were injected subcutaneously with 5×10 6 HLA-A2 + MAGE-A4 + A375 human melanoma tumor cells. On day 10 of the experiment, after the tumors had enough time to form, mice were intravenously injected with 4 × 10 6 T cells expressing control CAR (anti-HLA-A2 / HPV16E7 11-19 scFv, in VL-VH orientation) or anti-HLA-A2 / MAGE-A4 286-294 CAR (determined by the frequency of cells expressing GFP, a marker for cells that have been transduced with CAR). Specifically, mice (n=5 per group) were administered 4×10 6 irrelevant scFc CAR T cells (control scFv CAR) or 4×10 6 Anti-MAGE-A4 encoding 31345scFv CAR 286-294 CAR T. Tumor growth on day 52 was assessed by measuring tumor volume.
[0243] To determine tumor volume by external caliper gauges, the maximum longitudinal diameter (length in mm) and the maximum transverse diameter (width in mm) were measured. Tumor volume based on caliper gauge measurements was calculated by the following formula: Volume (mm 3 )=(length×width 2 ) / 2.
[0244] Table 8: HLA-A2 / MAGE-A4 286-294 - Targeted CAR T cells reduce tumor growth
[0245]
[0246]
[0247] *Control CAR T cells express anti-HLA-A2 / HPV16E7(11-19) scFv CAR
[0248] Table 9: HLA-A2 / MAGE-A4 286-294 -Directed CAR T cells promote survival
[0249]
[0250] Although A375 tumors progressively outgrew in mice receiving irrelevant scFv CAR T cells, the scFv encoding 31345 anti-HLA-A2 / MAGE-A4 286-294 CAR T cells expressing scFv CAR inhibited the growth of established A375 tumors in vivo and subsequently eradicated the tumors, as shown in Tables 8 and 9 and Figure 3A and Figure 3B shown.
[0251] Example 7: MAGE-A4-targeted CAR T cells reduce the growth of MAGE-A4-expressing tumors in vivo in a xenogeneic multiple myeloma model
[0252] To determine HLA-A2 / MAGE-A4 286-294 The in vivo efficacy of targeted chimeric antigen receptor (CAR) T cells was studied in xenografts in mice using IM9 human multiple myeloma tumor cells expressing MAGE-A4. scid Iq tm1Wjl / SzJ (NSG) mice were injected subcutaneously with 5×10 6 HLA-A2 + MAGE-A4 + IM9 human multiple myeloma tumor cells. On day 7 of the experiment, after the tumors had enough time to form, mice were intravenously injected with 4 × 10 6 T cells expressing control CAR (anti-HLA-A2 / HPV16E7(11-19) scFv in VL-VH orientation) or anti-HLA-A2 / MAGE-A4 286-294 CAR (determined by the frequency of cells expressing GFP, a marker for cells that have been transduced with CAR). Specifically, mice (n=5 per group) were administered 4×10 6 irrelevant scFc CAR T cells (control scFvCAR) or 4×10 6 Anti-MAGE-A4 encoding 31345scFv CAR 286-294 CAR T. Tumor growth on day 52 was assessed by measuring tumor volume.
[0253] To determine tumor volume by external caliper gauges, the maximum longitudinal diameter (length in mm) and the maximum transverse diameter (width in mm) were measured. Tumor volume based on caliper gauge measurements was calculated by the following formula: Volume (mm 3 )=(length×width 2 ) / 2.
[0254] Table 10: HLA-A2 / MAGE-A4286-294 - Targeted CAR T cells reduce tumor growth
[0255]
[0256] *Control CAR T cells express anti-HLA-A2 / HPV16E7(11-19) scFv CAR
[0257] Table 11: HLA-A2 / MAGE-A4 286-294 -Directed CAR T cells promote survival
[0258]
[0259] Although IM9 tumors progressively outgrew in mice receiving irrelevant scFv CAR T cells, the scFv encoding 31345 anti-HLA-A2 / MAGE-A4 286-294 CAR T cells with scFv CAR inhibited the growth of established IM9 tumors in 3 out of 5 mice and subsequently eradicated the tumors, as shown in Tables 10 and 11 and Figure 4A and Figure 4B shown.
[0260] Example 8: MAGE-A4-targeted CAR T cells reduce the growth of MAGE-A4-expressing tumors in vivo in a xenogeneic A375 melanoma model
[0261] Contains anti-HLA-A2 / MAGEA4 in VL-VH orientation 286-294 Chimeric antigen receptors of scFv plus 1) huCD8 hinge / transmembrane domain, 4-1BB co-stimulatory domain, and CD3z signaling domain (BB / z CAR) or 2) huCD28 hinge / transmembrane / co-stimulatory domain and CD3z signaling domain (28 / z CAR) using anti-HLA-A2 / MAGEA4 286-294 Antibody V L and V H Sequence, mAb31345 construction. As a non-binding control, BB / z CAR was designed using scFv plus huCD8 hinge / transmembrane domain, 4-1BB co-stimulatory domain, and CD3z signaling domain. These CARs were cloned into pLVX lentiviral vectors with EF1a promoter and IRES:eGFP sequence (for tracking CAR-transduced cells), and VSV pseudotyped lentivirus was produced.
[0262] CD3+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs) from two normal donors ('Donor 1' and 'Donor 2'), stimulated with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2, and transduced with lentivirus at an MOI = 5. The transduced cells were expanded with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2 for 19 days and then cryopreserved until use during in vivo experiments.
[0263] To determine HLA-A2 / MAGEA4 286-294 To investigate the in vivo efficacy of targeted chimeric antigen receptor (CAR) T cells, a xenograft study was performed. On day 0, immunodeficient NOD.Cg-Prkdc scid Iq tm1Wjl / SzJ (NSG) mice were injected subcutaneously with 5×10 6 HLA-A2 + MAGEA4 + A375 human melanoma tumor cells. Mass spectrometry was used to determine whether A375 melanoma cells expressed MAGEA4 286-294 On day 13 after tumor formation, mice (n=5 per group) were intravenously injected with 4×10 6 T cells expressing non-binding control BB / z CAR (control CART), anti-HLA-A2 / MAGEA4 286-294 BB / z CAR or anti-HLA-A2 / MAGEA4 286-294 28 / z CAR (determined by the frequency of cells expressing GFP, a marker for cells that have been transduced with CAR). Tumor growth on day 64 was assessed by measuring tumor volume.
[0264] To determine tumor volume by external caliper gauges, the maximum longitudinal diameter (length in mm) and the maximum transverse diameter (width in mm) were measured. Tumor volume based on caliper gauge measurements was calculated by the following formula: Volume (mm 3 )=(length×width 2 ) / 2.
[0265] Donor 1: A375 tumors received control CAR T cells or MAGEA4 286-294 In contrast, MAGEA4 286-294 28 / z inhibited the growth of established A375 tumors in vivo, with 1 of 5 mice being tumor-free at day 64. 286-294 28 / z CAR for MAGEA4 286-294The enhanced efficacy of BB / z CAR was confirmed as the tumor sizes on days 27, 29, 33, 36, 40 and 44 were statistically significant with p<0.0001 by 2-way ANOVA test.
[0266] Donor 2: A375 tumors growing in mice receiving control CAR T cells. 286-294 BB / z and MAGEA4 286-294 Treatment with both 28 / z CAR T cells inhibited A375 tumor growth, but with different kinetics. 286-294 28 / z CAR T cells acted with faster kinetics, eradicating tumors in 5 of 5 mice by day 27. MAGEA4 286-294 BB / z CAR T cells acted with slower kinetics, eradicating tumors in 5 of 4 mice by day 44. MAGEA4 286-294 28 / z CAR for MAGEA4 286-294 The enhanced kinetics of the anti-tumor activity of BB / z CAR was confirmed as the tumor sizes on days 19 and 22 were statistically significant with p=0.0071 and p=0.0008, respectively, by 2-way ANOVA test. Tables 12 to 27 provide a summary of these data.
[0267] Table 12: Data summary, day 7
[0268]
[0269] Table 13: Data summary, day 12
[0270]
[0271] Table 14: Data summary, day 15
[0272]
[0273]
[0274] Table 15: Data summary, day 16
[0275]
[0276] Table 16: Data summary, day 19
[0277]
[0278] Table 17: Data summary, day 22
[0279]
[0280] Table 18: Data summary, day 27
[0281]
[0282]
[0283] Table 19: Data summary, day 29
[0284]
[0285] Table 20: Data summary, day 33
[0286]
[0287] Table 21: Data summary, day 36
[0288]
[0289] Table 22: Data summary, day 40
[0290]
[0291] Table 23: Data summary, day 44
[0292]
[0293] Table 24: Data Summary, Day 48
[0294]
[0295] Table 25: Data summary, day 50
[0296]
[0297] Table 26: Data Summary, Day 57
[0298]
[0299] Table 27: Data Summary, Day 64
[0300]
[0301] These results indicate that the MAGE-A4-specific CAR disclosed herein has potent anti-tumor effects in vivo.
[0302] Example 9: MAGE-A4-targeted CAR T cells reduce the growth of MAGE-A4-expressing tumors in vivo in the xenogeneic SK-MEL-37 melanoma model
[0303] Contains anti-HLA-A2 / MAGEA4 in VL-VH orientation 286-294 Chimeric antigen receptors of scFv plus 1) huCD8 hinge / transmembrane domain, 4-1BB co-stimulatory domain, and CD3z signaling domain (BB / z CAR) or 2) huCD28 hinge / transmembrane / co-stimulatory domain and CD3z signaling domain (28 / z CAR) using anti-HLA-A2 / MAGEA4 286-294 Antibody V L and V H Sequence, mAb31345 construction. As a non-binding control, BB / z CARs were designed using different scFvs plus huCD8 hinge / transmembrane domains, 4-1BB costimulatory domains, and CD3z signaling domains. These CARs were cloned into pLVX lentiviral vectors with EF1a promoter and IRES:eGFP sequence (for tracking CAR-transduced cells), and VSV pseudotyped lentiviruses were produced.
[0304] CD3+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs) from two normal donors ('Donor 1' and 'Donor 2'), stimulated with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2, and transduced with lentivirus at an MOI = 5. The transduced cells were expanded with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2 for 19 days and then cryopreserved until use during in vivo experiments.
[0305] To determine HLA-A2 / MAGEA4 286-294 To investigate the in vivo efficacy of targeted chimeric antigen receptor (CAR) T cells, a xenograft study was performed. On day 0, immunodeficient NOD.Cg-Prkdc scid Iq tm1Wjl / SzJ (NSG) mice were injected subcutaneously with 5×10 6 HLA-A2 + MAGEA4 + SK-MEL-37 human melanoma tumor cells. Mass spectrometry was used to determine whether SK-MEL-37 melanoma cells expressed MAGEA4 286-294 On day 7 after tumor formation, mice (n=5 per group) were intravenously injected with 4×10 6 T cells expressing non-binding control BB / zCAR (control CAR T), anti-HLA-A2 / MAGEA4 286-294 BB / z CAR or anti-HLA-A2 / MAGEA4 286-29428 / z CAR (determined by the frequency of cells expressing GFP, a marker for cells that have been transduced with CAR). Tumor growth on day 64 was assessed by measuring tumor volume.
[0306] To determine tumor volume by external caliper gauges, the maximum longitudinal diameter (length in mm) and the maximum transverse diameter (width in mm) were measured. Tumor volume based on caliper gauge measurements was calculated by the following formula: Volume (mm 3 )=(length×width 2 ) / 2.
[0307] Table 28: Summary of CAR
[0308]
[0309] Donor 1: SK-MEL-37 tumors received control CAR T cells or MAGEA4 286-294 In contrast, MAGEA4 286-294 28 / z inhibited the growth of established SK-MEL-37 tumors in vivo. MAGEA4 was observed based on tumor size at days 31, 35, 40, 47, 55, and 62. 286-294 28 / z CAR for MAGEA4 286-294 The efficacy of BB / z CAR, the tumor size was statistically significant with p<0.0001 by 2-way ANOVA test.
[0310] Donor 2: SK-MEL-37 tumors growing in mice that received control CAR T cells. 286-294 Treatment with BB / z CAR T cells demonstrated efficacy and delayed tumor growth by approximately one week, and MAGEA4 286-294 The 28 / z CAR T cells strongly suppressed SK-MEL-37 tumor growth, with tumors reaching undetectable (untouchable) levels in five of five mice by day 20. These tumors remained undetectable from days 62 to 69, during which time the tumors recurred.
[0311] Overall, the results indicate that the MAGE-A4-specific CARs of the present disclosure demonstrated in vivo anti-tumor activity and anti-tumor kinetics (Tables 29 to 45).
[0312] Table 29: Data Summary, Day 6
[0313]
[0314]
[0315] Table 30: Data summary, day 11
[0316]
[0317] Table 31: Data summary, day 13
[0318]
[0319] Table 32: Data Summary, Day 18
[0320]
[0321] Table 33: Data summary, day 20
[0322]
[0323] Table 34: Data Summary, Day 24
[0324]
[0325] Table 35: Data Summary, Day 27
[0326]
[0327] Table 36: Data Summary, Day 31
[0328]
[0329] Table 37: Data Summary, Day 35
[0330]
[0331] Table 38: Data summary, day 40
[0332]
[0333] Table 39: Data Summary, Day 47
[0334]
[0335] Table 40: Data summary, day 55
[0336]
[0337] Table 41: Data summary, day 62
[0338]
[0339] Table 42: Data summary, day 69
[0340]
[0341] Table 43: Data summary, day 77
[0342]
[0343] Table 44: Data summary, day 84
[0344]
[0345] Table 45: Data summary, day 118
[0346]
[0347] Example 10: MAGE-A4 (230-239)-targeted CAR T cells reduce the growth of MAGE-A4-expressing tumors in vivo in a xenogeneic A375 melanoma model
[0348] Contains anti-HLA-A2 / MAGEA4 in VL-VH orientation 230-239 Chimeric antigen receptors of scFv plus 1) huCD8 hinge / transmembrane domain, 4-1BB co-stimulatory domain, and CD3z signaling domain (BB / z CAR) or 2) huCD28 hinge / transmembrane / co-stimulatory domain, and CD3z signaling domain (28 / z CAR) were used with V against mAb33229. L and V H Sequence construction. As a non-binding control, 28 / z CARs were designed using an irrelevant scFv plus huCD28 hinge / transmembrane domain / co-stimulatory domain and CD3z signaling domain. These CARs were cloned into pLVX lentiviral vectors with EF1a promoter and P2A:eGFP sequence (for tracking CAR-transduced cells), and VSV pseudotyped lentiviruses were produced.
[0349] CD3+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs) from normal donors, stimulated with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2, and transduced with lentivirus at an MOI = 5. The transduced cells were expanded with CD3 / CD28 microbeads plus 100 U / ml recombinant human IL-2 for approximately 14 days and then cryopreserved until use during in vivo experiments.
[0350] To determine whether anti-HLA-A2 / MAGEA4 230-239 To investigate the in vivo efficacy of targeted chimeric antigen receptor (CAR) T cells, a xenograft study was performed. On day 0, immunodeficient NOD.Cg-Prkdc scid Iq tm1Wjl / SzJ (NSG) mice were injected subcutaneously with 5×106 HLA-A2 + MAGEA4 + A375 human melanoma tumor cells. Mass spectrometry was used to determine whether A375 melanoma cells expressed HLA-A2 / MAGEA4 230-239 On day 13 after tumor formation, mice (n=4 or 5 per group) were intravenously injected with 4×10 6 T cells expressing non-binding control BB / zCAR (control CART), anti-HLA-A2 / MAGEA4 230-239 BB / z CAR or anti-HLA-A2 / MAGEA4 230-239 28 / zCAR (determined by the frequency of cells expressing GFP, a marker for cells that have been transduced with CAR). Tumor growth on day 28 was assessed by measuring tumor volume.
[0351] To determine tumor volume by external caliper gauges, the maximum longitudinal diameter (length in mm) and the maximum transverse diameter (width in mm) were measured. Tumor volume based on caliper gauge measurements was calculated by the following formula: Volume (mm 3 )=(length×width 2 ) / 2.
[0352] A375 tumors gradually grew in untreated mice and in mice that received control CAR T cells. Compared with control CAR T-treated mice, mice that received anti-HLA-A2 / MAGEA4 230-239 Mice receiving BB / z CAR T cells showed tumor control with decreased tumor growth on days 19 (p<0.02), 23 (p<0.02), and 26 (p<0.0001) (statistical data analyzed by 2-way ANOVA). 230-239 28 / z CAR T treatment also resulted in inhibition of established A375 tumor growth on days 19 (p=0.007), 23 (p<0.0001), and 26 (p<0.0001) (statistics analyzed by 2-way ANOVA). See Tables 46 to 54.
[0353] Table 46: Data Summary, Day 7
[0354]
[0355]
[0356] Table 47: Data Summary, Day 10
[0357]
[0358] Table 48: Data Summary, Day 13
[0359]
[0360] Table 49: Data Summary, Day 17
[0361]
[0362] Table 50: Data summary, day 19
[0363]
[0364]
[0365] Table 51: Data Summary, Day 23
[0366]
[0367] Table 52: Data Summary, Day 26
[0368]
[0369] Table 53: Data summary, day 33
[0370]
[0371] Table 54: Data Summary, Day 37
[0372]
[0373] Example 11: Structural Analysis of Fab / Soluble TCR Binding to HLA-A2 Binding MAGE-A4 (230-239) Peptide
[0374] To better understand the specific interactions between the antibody or TCR and the HLA-peptide complex, two x-ray crystal structures and three cryo-electron microscopy (cryo-EM) structures of antibody Fab fragments or engineered TCR soluble portions (sTCRs) bound to a complex of HLA-A2 and beta-2-microglobulin (HLA-A2 / b2m) showing the MAGE-A4 230-239 polypeptide in the HLA peptide binding groove were determined. The X-ray structures of the complex containing the two Fabs were 1.4 and The two Fabs have highly similar sequences and show almost identical binding modes. The CryoEM structure of the complex containing 33229 Fab is shown in Figure 2. The CryoEM structures of the additional Fab and sTCR were determined at and Resolution determination. Although the structures cover a range of resolutions, in each of the structures, the HLA-displayed MAGEA4:230-239 peptide residues are clearly visible in the electron / cryo-EM density map, allowing accurate determination of residue-level interactions between the HLA-displayed peptide and the complementarity determining regions (CDRs) of the Fab or sTCR.
[0375] The structures show that the Fab binds to the HLA-peptide complex in an overall similar orientation. The heavy chain CDR is located near the N-terminus of the peptide, and the light chain CDR is located near the C-terminus of the peptide. In each of the Fab binding structures, the solvent-exposed MAGE-A4 polypeptide residue arginine 235 is located near the center plane separating the heavy and light chain CDRs. The four Fabs recognize and bind three different rotational isomers of arginine 235. The rest of the peptide conformation displayed by HLA is very similar throughout the structure.
[0376] The sTCR binds to the HLA-peptide complex in an orientation typical of TCRs, with the α chain closer to the N-terminal side of the peptide and the β chain closer to the C-terminal side. The CDRs of the sTCR are closer to the N-terminus of the peptide relative to the Fab. The sTCR binds to a rotamer of peptide residue arginine 235 that is different from the rotamers observed in the four Fab-containing structures.
[0377] The contacts between Fab or sTCR and peptide are summarized in Table 55. "Contacts" here are defined as Fab / sTCR residues with non-hydrogen atoms located between The bound peptides are within the non-hydrogen atoms of the peptide displayed by HLA and may involve hydrogen bonding, charge-charge interactions or hydrophobic / van der Waals interactions. The bound peptides are numbered according to the residue position in the MAGE-A4 polypeptide as follows:
[0378]
[0379] The peptide contacts made by each Fab in the Fab are almost entirely concentrated in the CDRs HCDR3, LCDR1 and LCDR3. The HCDR3 of each antibody makes multiple contacts with the side chain of MAGE-A4 residue 233. The HCDR3 and / or LCDR3 of each Fab contacts the side chain of residue 235. The main chain carbonyl of peptide residue 236 contacts the LCDR1 of each Fab. None of the four Fabs contacts peptide residues 230, 231, 232, 234 or 239, most of which cannot bind to the Fab because they are buried in the HLA groove. Although peptide residue 234 is solvent exposed, the peptide residue lacks the ability to be a CDR contact as a glycine-restricted side chain. Nevertheless, substitutions at this glycine 234 may reduce the binding activity of these antibodies due to the resulting steric conflict between the larger peptide residue and the adjacent HCDR3 loop.
[0380] The sTCR contacts residue 233 through its α1 and α3 loops, and contacts peptide residue 235 through its β1 and β3 loops. Peptide residues 230, 231, 232, 234, 236, 237, 238, 239 do not contact the sTCR; thus, the peptide contact coverage of the sTCR is less complete than the peptide contact coverage of each of the Fabs mentioned above or than the peptide contact coverage observed in other structures of the TCR bound to a decameric peptide (e.g., PDB 3QDG).
[0381] Table 55: Peptide contacts
[0382]
[0383] Sequence Description
[0384] Table 56: Sequence Identifiers
[0385]
[0386]
[0387]
[0388]
[0389] Annotation sequence
[0390] In the following annotated sequences, the portions are identified by alternating non-underlined segments and underlined segments, and the order of the portions corresponds to the order listed below each sequence (i.e., the first non-underlined segment is VL, the next underlined segment is (G4S)3, the next non-underlined segment is VH, and so on).
[0391] MAGEA4(286 - 294)31345VL - VH BBz CAR P2A - GFP(SEQ ID NO:76)
[0392] DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK GGGGSGGGGSGGGGS QVQLVESGGGLVKPGGSLRLSCAASGFTFSEYYMTWIRQAPGQGLEWVSYISSSGFNIYYADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCAREGVTDGMDVWGQGTTVTVSS GGGGS TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR GSGATNFSLLKQAGDVEENPGPMMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATY GKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEG DTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPV LLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0393] VL
[0394] (G4S)3
[0395] VH
[0396] G4S
[0397] CD8 hinge / TM
[0398] 4 - 1BB co - stimulatory domain
[0399] CD3Z
[0400] P2A / GFP
[0401] MAGEA4(286 - 294)31345VL - VH CD28 hinge / TM / cytoCD3z CAR P2A - GFP(SEQ ID NO:77)
[0402] DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK GGGGSGGGGSGGGGS QVQLVESGGGLVKPGGSLRLSCAASGFTFSEYYMTWIRQAPGQGLEWVSYISSSGFNIYYADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCAREGVTDGMDVWGQGTTVTVSS GGGGS IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP FWVLVVVGGVLACYS LLVTVAFIIFWV RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS RVKFSRSADAPAYQQGQNQLYNEL NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY DALHMQALPPR GSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0403] VL
[0404] (G4S)3
[0405] VH
[0406] G4S
[0407] CD28 hinge
[0408] CD28 TM
[0409] CD28 co-stimulatory domain
[0410] CD3Z
[0411] P2A / GFP
[0412] MAGEA4(286 - 294)31345*VL - VH BBz CAR P2A - GFP(SEQ ID NO:78)
[0413] DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKR GGGGSGGGGSGGGGS QVQLVESGGGLVKPGGSLRLSCAASGFTFSEYYMTWIRQAPGQGLEWVSYISSSGFNIYYADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCAREGVTDGMDVWGQGTTVTVSS GGGGS TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR GSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDAT YGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFE GDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGP VLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0414] VL
[0415] (G4S)3
[0416] VH
[0417] G4S
[0418] CD8 hinge / TM
[0419] 4 - 1BB co - stimulatory domain
[0420] CD3Z
[0421] P2A / GFP
[0422] MAGEA4(286 - 294)31345*VL - VH CD28 hinge / TM / cytoCD3z CAR P2A - GFP(SEQ IDNO:79)
[0423] DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKR GGGGSGGGGSGGGGS QVQLVESGGGLVKPGGSLRLSCAASGFTFSEYYMTWIRQAPGQGLEWVSYISSSGFNIYYADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCAREGVTDGMDVWGQGTTVTVSS GGGGS IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP FWVLVVVGGVLACY SLLVTVAFIIFWV RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS RVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT YDALHMQALPPR GSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0424] VL
[0425] (G4S)3
[0426] VH
[0427] G4S
[0428] CD28 hinge
[0429] CD28 TM
[0430] CD28 co - stimulatory domain
[0431] CD3Z
[0432] P2A / GFP
[0433] MAGEA4(230 - 239)33229VL - VH BBz CAR P2A - GFP(SEQ ID NO:80)
[0434] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKRGKAPKLLIYDASILETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQFDNVPLTFGGGTKVEIK GGGGSGGGGSGGGGS EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIAYADSVKGRFTISRDNAKNSLYLQMNSLRSEDTALYHCAKDWRRTNYYGMDVWGQGTTVTVSS GGGGS TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR GSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDA TYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKF EGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDG PVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0435] VL
[0436] (G4S)3
[0437] VH
[0438] G4S
[0439] CD8 hinge / TM
[0440] 4 - 1BB co - stimulatory domain
[0441] CD3Z
[0442] P2A / GFP
[0443] MAGEA4(230 - 239)33229VL - VH CD28 hinge / TM / cytoCD3z CAR P2A - GFP(SEQ ID NO:81)
[0444] DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKRGKAPKLLIYDASILETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQFDNVPLTFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIAYADSVKGRFTISRDNAKNSLYLQMNSLRSEDTALYHCAKDWRRTNYYGMDVWGQGTTVTVSS GGGGS IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP FWVLVVVGGVLAC YSLLVTVAFIIFWV RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS RVKFSRSADAPAYQQGQNQLYN ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR GSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0445] VL
[0446] (G4S)3
[0447] VH
[0448] G4S
[0449] CD28 hinge
[0450] CD28 TM
[0451] CD28 co - stimulatory domain
[0452] CD3Z
[0453] P2A / GFP
[0454] The present invention is not limited to a certain scope by the specific embodiments described herein. In fact, various modifications of the present invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. A melanoma-associated antigen A4 (MAGE-A4) specific chimeric antigen receptor, comprising from N-terminus to C-terminus: (a) an extracellular ligand binding domain, wherein the extracellular ligand binding domain comprises an anti-MAGE-A4 antigen binding domain; (b) hinges; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain; wherein the extracellular ligand-binding domain is an anti-MAGE-A4 scFv domain, the anti-MAGE-A4 scFv domain comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR) connected by a linker, wherein the LCVR comprises LCDR1, LCDR2 and LCDR3 domains, and the LCDR1, LCDR2 and LCDR3 domains are shown in SEQ ID NOs: 12, 14 and 16, respectively, and the HCVR comprises HCDR1, HCDR2 and HCDR3 domains, and the HCDR1, HCDR2 and HCDR3 domains are shown in SEQ ID NOs: 4, 6 and 8, respectively.
2. A melanoma-associated antigen A4 (MAGE-A4)-specific chimeric antigen receptor, comprising from N-terminus to C-terminus: (a) an extracellular ligand binding domain, wherein the extracellular ligand binding domain comprises an anti-MAGE-A4 antigen binding domain; (b) hinges; (c) a transmembrane domain; and (d) a cytoplasmic domain comprising a co-stimulatory domain and a signaling domain; wherein the extracellular ligand-binding domain is an anti-MAGE-A4 scFv domain, the anti-MAGE-A4 scFv domain comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR) connected by a linker, wherein the LCVR comprises LCDR1, LCDR2 and LCDR3 domains, and the LCDR1, LCDR2 and LCDR3 domains are shown in SEQ ID NOs:61, 63 and 65, respectively, and the HCVR comprises HCDR1, HCDR2 and HCDR3 domains, and the HCDR1, HCDR2 and HCDR3 domains are shown in SEQ ID NOs:53, 55 and 57, respectively.
3. The chimeric antigen receptor of claim 1, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 37 and the HCVR comprises the amino acid sequence of SEQ ID NO:
2.
4. The chimeric antigen receptor of claim 2, wherein the LCVR comprises the amino acid sequence of SEQ ID NO:59 and the HCVR comprises the amino acid sequence of SEQ ID NO:
51.
5. The chimeric antigen receptor of claim 1, further comprising a peptide linker between the extracellular ligand binding domain and the hinge.
6. The chimeric antigen receptor of claim 2, further comprising a peptide linker between the extracellular ligand binding domain and the hinge.
7. The chimeric antigen receptor according to any one of claims 1-6, wherein the linker or the peptide linker comprises an amino acid sequence selected from SEQ ID NOs: 23-26.
8. The chimeric antigen receptor of any one of claims 1-6, wherein the hinge is a hinge from a CD8α polypeptide, the transmembrane domain is a transmembrane domain from a CD8α polypeptide, the co-stimulatory domain is a 4-1BB co-stimulatory domain, and the signaling domain is a CD3ζ signaling domain.
9. The chimeric antigen receptor of any one of claims 1-6, wherein the hinge is a hinge from a CD28 polypeptide, the transmembrane domain is a transmembrane domain from a CD28 polypeptide, the co-stimulatory domain is a CD28 co-stimulatory domain, and the signaling domain is a CD3 zeta signaling domain.
10. The chimeric antigen receptor according to claim 8, wherein: (a) the hinge comprises the amino acid sequence of SEQ ID NO: 27; (b) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 28; (c) the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 29; or (d) the signaling domain comprises the amino acid sequence of SEQ ID NO:
30.
11. The chimeric antigen receptor of claim 9, wherein: (a) the hinge comprises the amino acid sequence of SEQ ID NO: 41; (b) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 43; (c) the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 45; or (d) the signaling domain comprises the amino acid sequence of SEQ ID NO:
30.
12. The chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
39.
13. The chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
47.
14. The chimeric antigen receptor of claim 2, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
71.
15. The chimeric antigen receptor of claim 2, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
73.
16. An isolated nucleic acid molecule encoding the chimeric antigen receptor of any one of claims 1-15.
17. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 12, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:
38.
18. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 13, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:
48.
19. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 14, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:
70.
20. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 15, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:
72.
21. A vector comprising the nucleic acid molecule of any one of claims 16-20.
22. The vector according to claim 21, wherein the vector is a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector or a retroviral vector.
23. A cell comprising the nucleic acid molecule of any one of claims 16-20.
24. A cell comprising the vector of claim 21 or 22.
25. The cell according to claim 23, which is a human T cell.
26. An engineered cell comprising the chimeric antigen receptor of any one of claims 1-15.
27. The engineered cell of claim 26, wherein the engineered cell is an immune cell.
28. The engineered cell of claim 26, wherein the engineered cell is an immune cell, and the immune cell is an immune effector cell.
29. The engineered cell of claim 26, wherein the engineered cell is a T lymphocyte.
30. The engineered cell of claim 26, wherein the engineered cell is a T lymphocyte, and the T lymphocyte is an inflammatory T lymphocyte, a cytotoxic T lymphocyte, a regulatory T lymphocyte, or a helper T lymphocyte.
31. The engineered cell of claim 29, which is a CD8+ cytotoxic T lymphocyte.
32. An engineered cell population obtained by: (a) providing an immune cell population obtained from a subject; (b) introducing a nucleic acid molecule encoding the chimeric antigen receptor of any one of claims 1 to 15 into an immune cell; (c) culturing immune cells under conditions where the nucleic acid molecule is expressed; and (d) Isolating immune cells expressing chimeric antigen receptors on their surface.
33. A pharmaceutical composition comprising one of the following: (a) a genetically modified human T cell and a pharmaceutically acceptable carrier, wherein the genetically modified human T cell comprises a chimeric antigen receptor according to any one of claims 1 to 15; or (b) the engineered cell according to claim 26 and a pharmaceutically acceptable carrier; or (c) the engineered cell according to claim 27 and a pharmaceutically acceptable carrier; or (d) the engineered cell according to claim 28 and a pharmaceutically acceptable carrier; or (e) the engineered cell according to claim 29 and a pharmaceutically acceptable carrier; or (f) the engineered cell according to claim 30 and a pharmaceutically acceptable carrier; or (g) The engineered cell according to claim 31 and a pharmaceutically acceptable carrier.
34. Use of the engineered cell of any one of claims 26-31 or the engineered cell population of claim 32 for the preparation of a medicament for treating a cancer expressing MAGE-A4 in a subject, wherein the cancer expressing MAGE-A4 is multiple myeloma expressing MAGE-A4 or melanoma expressing MAGE-A4.
35. The use according to claim 34, wherein the subject is a human subject.
36. The use according to claim 34 or 35, wherein the MAGE-A4 expressing cancer is a MAGE-A4 expressing melanoma.
37. The use according to claim 34 or 35, wherein the cancer expressing MAGE-A4 is multiple myeloma expressing MAGE-A4.
38. A method of engineering a cell population to express a chimeric antigen receptor according to any one of claims 1-15, the method comprising: (a) providing immune cell populations; (b) introducing a nucleic acid molecule encoding the chimeric antigen receptor of any one of claims 1 to 15 into an immune cell; (c) culturing immune cells under conditions where the nucleic acid molecule is expressed; and (d) isolating immune cells expressing the chimeric antigen receptor on the cell surface.
39. The method of claim 38, wherein the immune cell population of (a) is obtained from a subject.
